OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← Entuk

2024-09-30-accounts

ENTUK

formally known as ENT UK trading as British Academic Conference in Otolaryngology (BACO) and British Association of Otorhinolaryngology - Head and Neck Surgery (BAO-HNS) COMPANY REGISTRATION NUMBER: 06452601 CHARITABLE COMPANY REGISTRATION NUMBER: 1125524

BACK TO THE

TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 1 |

It gives me great pleasure to write this foreword in my first year as President. It marks the first year of working towards our 5- year strategy, Inspiring Excellence and Shaping the Future, which allows us to see just how much we have achieved, but equally where our resources need to be focussed in the years to come.

The report illustrates just how many people are involved at all levels promoting and developing our specialty through ENTUK and our membership and special interest groups. I am delighted we have furthered our collaborations, developing partnerships with the British Laryngological Association (BLA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) and Fifth Sense. I am very grateful to all who have contributed over the past year.

We have further cemented our relationship with the ENTUK Foundation, our philanthropic arm, and have seen the launch of ENTUK Enterprises as our business arm.

I would like to highlight two notable clinical research achievements for our speciality. Two major NIHR-funded randomised trials have provided for the first time clinical evidence that surgery is effective for some of our most common conditions, namely Tonsillectomy in adults (NATTINA) and Septoplasty (NAIROS). This is not only important for the clinicians that we represent but particularly for our patients.

Outside the speciality, we continue to have close links with the four surgical Royal Colleges and through the Federation of Speciality Associations (FSSA) the other SA’s. Our links with GIRFT and NHSE have strengthened, and guidance continues to be developed in collaboration.

We look forward to the opportunities for growth and development in the coming year and to our annual meeting in Birmingham in June and our research and awards meeting in September, which promise to be a great opportunity for networking and learning.

Miss Helen Cocks

President of ENTUK

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 2 |

As the professional membership body representing ear, nose and throat surgery and its related specialities in the United Kingdom, we were delighted to publish our first five-year strategy in 2023. This has been its first full year of delivery and we have made steady progress across a range of activities all contributing to our ambition to Inspire Excellence and Shape the Future.

Inspiring Excellence and Shaping the Future

To inspire Excellence we have:

To Shape the Future we have:

You will read about this and much more in the following pages – all of which is guided by our strategy and vision of a world where ENT and head and neck medical professionals can succeed and provide the best healthcare to patients

In 24/25 we are committed to reviewing our achievements, progress towards our strategic goals and the environment in which we operate. Our aim is to ensure current plans remain relevant, create new workplans where necessary, make certain we represent the ENT community, offer the best training and guidance and deliver maximum value to our members.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

3

The following sets out the management and governance of ENTUK during this financial year.

This financial year, ENTUK set up a trading arm to deliver all the business-related activities of ENTUK so that the Association can solely focus on its membership and charitable aims. ENTUK Enterprises Ltd was incorporated on 14 April 2024 as a private company limited by shares with ENTUK as the sole shareholder and came into operation on 1 October 2024.

ENTUK Enterprises Ltd will deliver the annual calendar of events including BACO, courses, admin services and any commercial activity such as consultancy. This enables ENTUK to make savings and protects the Association from the risks of any commercial ventures meaning it is using its resources more effectively. ENTUK Enterprises Ltd is overseen by a Board of Directors.

ENTUK office

The Board of Trustees

Demitted from the Board of Trustees

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

4

The Executive Committee

Demitted from the Executive Committee

The Finance Committee

Demitted from the Finance Committee

The Education & Training Committee (ETC)

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

5

Demitted from ETC

The ENTUK Foundation Committee

Demitted from the Foundation Committee

The ENTUK Council

Regional Council Members

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

6

Demitted from Council

Our Representatives

The work of ENTUK is supported by ENTUK Member representatives on many external groups and organisations. These roles approved by the ENTUK Executive Committee and are appointed either by open advertisement and interview or through the recruitment processes of the group or organisation. We are very grateful for the time, expertise and commitment of these representatives.

The below list sets out the ENTUK Representatives on external groups and organisations during the financial year:

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

7

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

8

ENTUK Annual General Meeting (AGM)

The AGM 2024 took place on 15 April during the ENTUK Spring Meeting. We had a minute’s silence to remember colleagues, including ENTUK Lay Trustee Andrew Foster, who had all sadly passed away during the past year.

Incoming President Miss Helen Cocks invited outgoing President Mr Andrew Swift to share the highlights of the year, including rising to the healthcare challenges to fully support the membership and contributing to developing healthcare strategies for the future. The success of BACO International 2023 was applauded, which had been recognised by two National Association Excellence Awards. Andrew highlighted ENTUK’s involvement in the Royal College of Surgeons of England Census, collaboration with Getting It Right First Time (GIRFT), workforce numbers and the development of many important guidelines for the specialty.

Mr William Hellier, ENTUK Honorary Treasurer provided a clear summary of the Association finances. He proposed that the Consultant member fee be reduced from £560 to £495 for 2024/25, returning it to the level it was two years prior. This would be kept at this rate for two years. The membership fees for other grades, including Young Consultants, would be frozen for two years. This was approved by the members present.

Helen thanked Miss May Yaneza (Honorary Secretary), Mr Tim Mitchell (Clinical Trustee) and Mr Andrew Gamble (Lay Trustee) who had stepped down over the past year for their contribution and work on the ENTUK Board of Trustees.

Andrew finished the meeting by announcing that Professor David Howard, Professor Chris Raine, Mr Shyam Singam, Professor Philippa Tostevin and Professor Tim Woolford had been awarded Honorary membership.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 9 |

During the 2023/24 financial year, ENT UK welcomed 310 new paying members.

Membership income by year

Year
Revenue
YoY%
Headcount
YoY%		 Year
Revenue
YoY%
Headcount
YoY%		 Year
Revenue
YoY%
Headcount
YoY%		 Year
Revenue
YoY%
Headcount
YoY%		 Year
Revenue
YoY%
Headcount
YoY%
2014-15 325k 1,262
2015-16 342k 5 1,340 6
2016-17 371k 8 1,387 4
2017-18 410k 11 1,485 7
2018-19 411k 0 1,617 9
2019-20 434k 5 1,880 16
2020 -21 448k 3 2,117 13
2021–22 448k - 2,427 15
2022-23
~~—EoEEEEOEE~~		 481k.
~~—EoEEEEOEE~~		 8
~~—EoEEEEOEE~~		 2,370
~~—EoEEEEOEE~~		 -2
~~—EoEEEEOEE~~
2023-24
~~—EoEEEEOEE~~		 ~500k.
~~—EoEEEEOEE~~		 3
~~—EoEEEEOEE~~		 2337
~~—EoEEEEOEE~~		 -2
~~—EoEEEEOEE~~
Paying members by grade
Thisyear
Lastyear		 Paying members by grade
Thisyear
Lastyear		 Paying members by grade
Thisyear
Lastyear
Total 2,337 2,370
~~es~~
Consultant 541 558
~~es~~
~~oO~~
Trainees 594 555
~~oO~~
SFO 526 556
International 189 204
YCOHNS 153 171
Associate 153 149
Allied 119 120
Retired 62 57
Free members
Thisyear
Lastyear		 Free members
Thisyear
Lastyear		 Free members
Thisyear
Lastyear
Total 458 331
Hinari 333 192
Life 67 81
Honorary 44 47
Parental leave
~~a~~		 8
~~a~~		 11
~~a~~
Lay
~~a~~		 6
~~a~~		 -
~~a~~

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

10

Membership Developments

We continue to promote a new tailor-made Medical Indemnity Insurance Scheme which was launched in 2022. ENT UK arranged for Howden Insurance Brokers Ltd. to provide this scheme, to ensure that members can access suitable, up-to-date indemnity cover and protection. The risks inherent to frontline surgery mean that access to suitable indemnity cover is vitally important to our members, as well as to the specialty in general.

The recently developed ENT UK website continues to evolve and we are pleased that members are using the new members’ area to register for events, submit abstracts and apply for grants and fellowships. We will continue to upgrade the section for professionals to help members to better navigate our growing library of high-quality resources. This year we also re-launched the ‘find a surgeon’ tool on the website

You can read more about the impact we are having for our members in the following chapters.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

11

Partnerships play a crucial role in the delivery of our mission, and we are passionate about nurturing these relationships and collaborating with various organisations, associations, and charities that share our values and goals. This year has marked significant developments in the area.

During 23/24 we successfully established strategic collaborations with the charity Fifth Sense, focusing on the exchange of vital information, specialised training, and valuable resources. Together we aim to enhance the standard of care for individuals suffering from smell and taste disorders..

We also formed a promising partnership with the British Laryngology Association, to develop surgical education, training, and research in otolaryngology further together. Our ongoing collaboration with the Association of Otolaryngologists in Training (AOT) remains strong, allowing us to continually share knowledge and experiences.

We also engage with a range of associations, including the British Association of Paediatric Otolaryngologists (BAPO), the British Association of Endocrine and Thyroid Surgeons (BAETS), and the Confederate of European Otorhinolaryngologists and Head and Neck Surgeons (CoE ORL-HNS), with the shared goal of developing high-quality clinical guidelines and informative resources for patients. These collaborative efforts ensure that ENTUK members have access to a diverse array of events, training opportunities, and resources that enhance their professional development and improve patient care.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

12

The Association of Otolaryngologists in Training (AOT)

It is my great pleasure to be the new President of The Association of Otolaryngologists in Training (AOT) - our trainee-led organisation which has been running since its inception in 1989.

As Vice President last year, I saw first-hand the excellent progress made by the previous President, Mr Anthony Bashyam. Two of the changes made demonstrate AOT’s ongoing commitment to advocacy for all trainees in keeping with our Equality, Diversity and Inclusion (EDI) strategy: for the first time, the committee applications were held online and judged anonymously; and a less than full-time (LTFT) representative was introduced to our Committee. We also held our National Conference in Leeds, which was attended by over 200 people and covered important training and curriculum changes.

In the upcoming year, we look forward to launching the AOT Podcast which will be a really useful resource for trainees, especially in preparing for the FRCS exams. We will be introducing our new AOT grants and prizes in collaboration with The Association of Surgeons in Training (ASiT) and ENTUK Global Health which will enable trainees to visit the work performed in low and middle-income countries. We were also grateful to be granted funding from the ENTUK Foundation for our DOHNS course, aimed to help junior trainees gain the knowledge and content previously covered by the DOHNS exam pathway; the first course will be delivered as the exam is phased out.

We hope to further develop our excellent working relationship with ENTUK. If you aren’t already, please do join us as an AOT member - it’s completely free and open to anyone, especially foundation and core trainees interested in ENT and ENT registrars: https://aotent.org

Ms Eleanor Crossley AOT President

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

13

Clinical Guidelines

During this financial year, ENTUK has worked with external organisations and our ENTUK sub-groups to develop new and update existing guidelines for the benefit of all those working within ENT departments. We have also provided guidance to Getting it Right First Time (GIRFT) and other organisations to ensure consistent guidance and recommendations.

In an important development for ENT, Newcastle University’s NIHRcommissioned NATTINA trial concluded that adult tonsillectomy for recurrent tonsillitis is effective both clinically and in terms of cost. The multicentre trial, the largest of its kind, found that patients who underwent a tonsillectomy had 50% fewer occurrences of sore throat over two years, compared to patients who did not. The findings have significantly reduced the previous evidence gap and challenged the assertion that the procedure was of limited clinical value.

ENTUK and NHSE collaborated to publish a ‘Decision Support Tool: Making a Decision about Recurrent Tonsillitis in Adults and Children’ that should aid both patients and clinicians. The document also includes the most recent information from the NATTINA trial. Easy accessibility for patients and widespread dissemination within primary care could make a significant difference to clinical management and referral patterns.

Mr Sean Carrie and Mr James O'Hara led the first randomised controlled trial to study the effectiveness of septoplasty in the UK. The National Airways Obstruction Study (NAIROS) compared septoplasty with medical therapy (isotonic saline spray plus mometasone spray) in 378 patients recruited from 17 hospitals. Using the SNOT-22 scores as the primary outcome measure, this publication clearly shows the superiority of septoplasty in comparison to medical therapy. This was true of patients with at least moderate nasal obstruction but showed greater improvement in those with more severe symptoms. The findings, published in October 2023, will be invaluable to discussions with health commissioners to improve the equity of access to septoplasty across the UK and will, at last, refute claims that septoplasty is an operation of limited clinical effectiveness.

ENTUK has committed to lead activity in relation to Sustainability in ENT and Head and Neck Healthcare . As a starting point, we want to address the areas which are most relevant and where we can have impact. These are suction, flexible nasal endoscopy and outpatient instruments. This work was led by Professor Mood Bhutta, Miss Phui Yee Wong and Mr Mark Williams. These guidelines will be published shortly to give our members confidence in making decisions that are best for their patients and the planet.

ENTUK collaborated with the Institute for Addressing Strangulation (IFAS), major royal colleges, and associated professional groups to develop comprehensive guidelines for the Clinical Management of Non-fatal Strangulation . These

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

14

guidelines aim to provide victims with optimal care promptly and mitigate potential harm.

The British Association for Paediatric Otorhinolaryngology (BAPO), in collaboration with several organisations including ENTUK, released new guidance to support surgical units undertaking Adenotonsillectomies in Children as Day Cases . This is to support them in achieving the target for day case surgery recommended by GIRFT.

With the support of ENTUK, BAPO also published guidelines for the Management of Non-tuberculous Mycobacterial Cervical Lymphadenitis . This is a useful piece of work about a condition whose management remains contentious.

New guidance, jointly written by BRS , BSFPS and ENTUK, was published on the clinical management of Cocaine-induced ENT Pseudo-GPA. Cocaine has always been known to adversely affect the nose, often resulting in perforations of the nasal septum. However, over the last couple of decades, patients with known cocaine abuse have presented with severe nasal deformities and associated tissue loss affecting the nose, face and palate.

The Royal College of Surgeons of England published the results of the 2023 Surgical Workforce Census in their report 'Advancing the Surgical Workforce: 2023 UK Surgical Workforce Census Report '. This provided comprehensive information on the composition of the surgical workforce, its demographics and working practices. Due to the efforts of the SAC, we have our own evidence to highlight the concerns more specifically in ENT, and ENTUK published a statement on the Census.

ENTUK has also been involved in the review of a number of national consent forms for commonly performed procedures in ENT. These have been written by NHSE with GIRFT and some are now available online for routine use.

Button batteries continue to cause considerable morbidity and, sadly, mortality despite the gold standard pathway that requires all batteries to be removed within two hours of ingestion and certainty of presentation if the time of ingestion is unknown. To this end, ENTUK has been working with the national body led by Mr Ian Sugerman and Miss Nara Orban with support from the working group. At the present time, data is being collected to establish how a gold standard Button Battery pathway may be delivered and potential barriers to the same.

Thanks to Miss May Yaneza, past ENTUK Honorary Secretary, for her work on clinical guidelines during her tenure and her diligence and attention to detail.

Miss Nara Orban

ENTUK Honorary Secretary

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 15

ANNUAL REPORT 2023 - 2024 ||

Patient Information leaflets

This year has been busy for the patient information leaflets team. Between 2023 and 2024, we have published 21 patient information e-leaflets on the ENTUK website, with 12 leaflets currently being reviewed by the team. These include six on voice, four paediatric, one on facial palsy and one on vertigo. Thank you to all the authors who have contributed their time and expertise over the year.

We have made progress in updating our processes to align with the Patient Information Forum (PIF) TICK assessment criteria, and we expect to confirm accreditation in December 2024. Being PIF TICK certified will give further credibility to our patient leaflets and demonstrate that we follow best practices in ensuring clinical accuracy and accessibility in our resources. As part of our continuing efforts to improve patient engagement, a feedback survey function has been added to the website. This has allowed us to capture a wider range of user feedback from both patients and healthcare professionals.

As part of ENTUK’s partnership with Fifth Sense and Tinnitus UK, we now host links to their specialist patient information resources on the ENTUK website. We also continue to receive excellent feedback from the BAPO team on the current paediatric leaflets, and they have been working with us to develop new leaflets. The e-leaflets page now has a separate paediatrics section for ease of navigation. A communications strategy has been developed to promote ENTUK’s approach to patient information and the new and updated e-leaflets which have recently been published. New leaflets are promoted on social media, and regular updates included in the Newsletter. The leaflets have also been promoted at external events which have been well-received and generated more user engagement.

We are excited to continue expanding the information leaflets in the coming year, including potentially developing information in new formats, such as a short, animated video series.

Patient Information Team

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 16

ANNUAL REPORT 2023 - 2024 ||

National Clinical Impact Awards

The new National Clinical Impact Award (NCIA) scheme was introduced two years ago and is now finishing its second cycle. The main change in the new scheme was the removal of citations and ranking by specialist societies such as ENTUK, though employer support was still required. There was an increased number of awards, 600 in England and 37 in Wales, and the awards were based on submissions which highlighted impacts from activities rather than the activities themselves.

Changes were introduced to the application process with only one application required and ranking determining the level of award. The new levels were National (N0 – Wales), N1, N2, N3 with increasing levels of payment for each. The domains were as follows:

Less than Full Time (LTFT) award holders receive the full value of the award if eligible (i.e. job plan has minimum 3 NHS clinically-relevant PAs) and there were no renewals for awards which are non-pensionable. The essentially competitive and regional nature of the scheme remained and the need to demonstrate ‘over and above’ performance with increased emphasis on national impact. The aim was to increase the opportunity to obtain higher awards more quickly, fostering diversity and turnover.

The message to encourage members to apply was delivered by ENTUK in a webinar in conjunction with the Royal College of Surgeons Edinburgh (RCSEd) and a presentation to Young Consultants (YCOHNS) at their Annual Meeting held in in Birmingham on 10 November 2023 was well received.

The removal of selective ranking and citations by ENTUK and other specialist societies and colleges was conveyed to delegates and in information on NCIA through the ENTUK Newsletter. ENTUK aims to disseminate relevant information from the Advisory Committee on Clinical Impact Awards (ACCIA) to provide guidance and assistance to an unlimited number of applicants to improve the quality of applications. Unlike in previous years, ACCIA forbids ENTUK and other societies from critique and editing individual applications from members.

More information and advice is available from the ACCIA .

Professor Nirmal Kumar ENTUK NCIA Lead

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 17

ANNUAL REPORT 2023 - 2024 ||

Mentoring

ENTUK Mentoring Scheme

Hosted and led by WENTS UK

Since the scheme’s launch in 2020, WENTS UK has matched and supported volunteer mentor-mentee pairings and there are now over 120 matched pairs. The scheme was paused to new members in 2024 while ENTUK reviewed its operation and governance.

We would like to take this opportunity to acknowledge and thank all our mentors, who are kindly volunteering within the scheme – it would not exist without your kindness, effort and engagement.

ENTUK CESR Buddy Scheme

Each year, fewer than ten ENT specialty doctors apply for specialist registration via the CESR route in the UK. This is an expensive process and the support for these doctors in preparation for their submission is variable around the UK, due to the variety of experience that may be available in each region. The aim of this voluntary ‘buddy’ scheme is to provide informal support and advice to a colleague in order to maximise their chance of success in what is a very expensive process.

There has been great interest from our consultant members in supporting this mentorship scheme. Mentors have been able to support colleagues through the CESR process as a result of their own experience of applying via this route. We are enormously grateful for this mentorship and the support of surgeons who will take an alternative pathway through their career development in ENT.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

18

The ENTUK Foundation

The ENTUK Foundation is ENTUK’s philanthropic arm which aims to improve ENT healthcare for all. The Foundation seeks to achieve this by:

Importantly, the Foundation Committee has been successfully raising funds from private individuals and industry partners since its inception in 2021, and the achievements of the Foundation would not have been possible without the generous support of these donors.

Since its inception, the Foundation has raised more than £200,000 and in the three years of the Foundation Education and Research Grants Programme, more than 60 research projects, 20 education projects and several international collaborations have been delivered.

This year also saw the launch of the Foundation’s Philanthropic Circle and a donor celebratory lunch was held in September in appreciation of the donors who supported the Foundation and hopefully to also encourage more donations and contributions going forwards.

The project highlights this year include a young UK consultant participating in the specialised airway course in Pune India, spreading the learning and upholding standards of practice around the world. A visiting fellow (Prof VS Rokade fellowship) from Tanzania to the UK supported by the College of South, East and Central Africa (COSECA) and Netcare Foundation funded by the ENTUK Foundation was another highlight. Other ongoing international projects include the ear aid project in Nepal and other projects in Africa.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

19

The 2024 round of ENTUK Foundation Awards received many applications for grant funding and 10 Education Grants totaling £12,865 and 7 Research Grants totaling £9,000 were awarded. Two additional international collaborations were also supported. These awards were presented to the recipients at the Research Showcase event held in York on 4 October. Details of all the Foundation Award recipients, their projects and award amounts can be found on the ENTUK website. ~~oo~~

The event also celebrated the achievements of past recipients of the Foundation Awards with several completing higher degrees and going on to receive further recognit ion and support from leading grant awarding bodies such as the National Institute of Health Research (NIHR) and Research for Patient Benefit (RfPB) grants.

Delegates also heard from the finalists of the ENTUK Foundation Research and Training Prizes in memory of Rowena Ryan, and we congratulate all the winners of these National Awards.

At the event, ENT UK President Miss Helen Cocks presented the ENTUK and Foundation Lifetime Trainer Award 2024 to Prof Patrick Bradley for his distinguished contribution to the specialty over many decades. Congratulations also go to Mr Shahz Ahmed who received the ENTUK and Foundation Best Trainee Nominated Trainer Award 2024 .

The Foundation Committee, assisted by its Advisory Group has improved the governance of the Foundation and we thank the Lay and ENTUK Members who have contributed to the success of the Foundation with their expertise and time. The Foundation is passionate about continuing its activity focused on research and education, social responsibility, professional development, patient and public involvement and engagement, and celebration.

Professor B Nirmal Kumar

ENTUK Foundation Committee Chair

Miss Katie Nurcombe ENTUK Foundation Secretary

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

20

Equity, Diversity and Inclusion

Our Equity, Diversity and Inclusion goals are that:

Following the publication of its first Equity, Diversity and Inclusion Strategy and Action Plan in the previous year, a new Action Plan for 2023/24 was developed. Regular reports were provided to Trustees during the year and a brief update can be found below:

A new Action Plan for 2024/25 will be produced in line with the ENTUK Business Plan.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

21

This report covers the educational activities of ENTUK in this financial year.

The ENTUK Education and Training Committee (ETC) meetings took place virtually this year. The ETC consists of representation from the leadership of established educational groups including the ENTUK Continuing Professional Development Committee, SFO, SAS, AOT, SAC and the ENTUK Community Group with the role of advising on training and CPD. Updates have been provided to the ENTUK Executive Committee, Board of Trustees and Council throughout the year.

This report represents a summary of educational activities to demonstrate how they have progressed in alignment with the mission statement of ENTUK, noting the strategic objectives and key deliverables in the previous 5–10-year strategy document.

1. Mission statement:

To promote an understanding of the range of conditions treated by the specialty

e-lefENT

Lead: Mr James Tysome and Ms Somiah Siddiq

The Director of e-learning, Mr James Tysome, and Editor-in-Chief of e-lefENT, Ms Somiah Siddiq, met with others in elefENT strategy meetings to explore the options for future funding of the online learning platform.

The e-lefENT resources have been mapped to the following syllabuses (by Nina Mistry):

Web developers have been tasked to include syllabus mapping with hyperlinks to improve platform navigation for learners.

The subsection editors have modules awaiting review and upload (3 in paediatric ENT; 2 in otology; 1 in laryngology; 2 in rhinology) as well as updating old content. This continuous evolution of the platform provides a highly valuable current resource for trainees and for CPD refreshers for everyone.

To support global access to e-lefENT, Hinari A and Hinari B countries have free access to e-lefENT. Hinari A countries first apply to become ENTUK member (free) and then have access to all resources including e-lefENT. For Hinari B countries, only e-lefENT access is free and they apply for an account directly from the e- lefENT account.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

22

Guidelines Live 2023

ENTUK supported the ENT session at this meeting attended by general practitioners, pharmacists and other allied healthcare professionals. This year the session held on 22 November2023 was chaired by Mrs Alison Hunt and all talks received excellent feedback:

2. Mission statement:

To support and provide continuing education for specialists

CPD

Lead Miss Marianne Elloy

The Continuing Professional Development (CPD) Committee led by Miss Marianne Elloy has provided kite mark accreditation on behalf of ENTUK as a marker of quality of educational provision.

CPD Applications

The Committee have processed 38 CPD applications in the last 12 months. The majority of meetings and courses are now face to face with occasional hybrid / virtual meetings.

Quality Assurance

Two quality assurance course inspections have been successfully undertaken and demonstrated the provision of high-quality educational events using hybrid learning styles and clear educational objectives. Review of course and meeting feedback demonstrated that learners’ needs and expectations were met with no outlying events identified.

Updates

Acknowledgements

The Committee would like to thank Ms Janet Stephen, ENTUK Education & Governance Officer for her ongoing hard work and commitment to support the Committee.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

23

Webinars

Leads Mrs Jaya Nichani and Ms Emily Lowe (trainee)

The webinar series is a free resource that is livestreamed through the Royal College of Surgeons of Edinburgh (RCSEd). The new series “Updates in ENT” started with Recurrent Respiratory Papillomatosis (10 September 2024). Two webinars are planned in the next financial year including Sinonasal Neoplasia (10 October 2024) and Sudden Sensorineural Hearing Loss: Management and Challenges (19 November 2024).

The webinars are also stored in the Education Library on the ENTUK website and represent a valuable resource for trainees.

Paediatric Emergency Surgical Skills Course (PESC)

Leads Mr Sunil Sharma, Mrs Jaya Nichani and Ms Emily Lowe (trainee)

This simulation course has been developed primarily to support ENT consultants who cover emergency work but who do not work in tertiary paediatric ENT centres. No course was delivered this year but one is planned for February 2025. These courses will not be exclusive for ENTUK members, but members will have a reduced course fee, and the course will initially be advertised to ENTUK members.

Adult Emergency Surgical Skills Course (ESSC)

Course Lead Ms Louise Melia with Mr Vikas Acharya (trainee)

A Course Lead was appointed and whilst no course was delivered in this financial year, significant work took place to understand the arrangement for this course. Work is underway to evolve the delivery of this course to ensure it is costeffective.

Podcast development

Lead Mr James Tysome

Mr James Tysome devised the concept of ‘A coffee room chat in ENT’, with support from the RCSEd. Although these were no further podcasts this year, a further new series of podcasts to be held by ENTUK in collaboration with the RCSEd is planned. These podcasts involve a significant amount of work and it is anticipated that Mr Tysome will be supported by a trainee lead.

Education Library

The Education Library is a valuable repository on the new website for useful educational resources and continues to be expanded with the upload of webinars initially uploaded to the RCS Ed website.

ENTUK Foundation Awards

Successful recipients of the ENTUK Foundation Education Grants were announced at the ENTUK Research Showcase meeting on 4 October 2024. Details of the winners can be found on the ENT UK website.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 24

ANNUAL REPORT 2023 - 2024 ||

3. Mission statement:

To encourage recruitment into the specialty

Association of Otolaryngologists in Training (AOT)

A key educational relationship that has been actively nurtured throughout the year is that between ENTUK and the AOT group. The President of AOT and the education representatives have been active contributors to the Education and Training Committee and as such provide a key bridge of essential communication between the organisations. The AOT are in the process of developing an FRCS podcast supported by a grant awarded by the ENTUK Foundation.

Medical Training Initiative (MTI)

The MTI scheme is run by HEE on behalf of the Department of Health (the government sponsor) operating under the Home Office Tier 5 Government Authorised Exchange visa scheme. In alignment with the strategic objective to run an effective recruitment scheme for MTI, ENTUK aims to sponsor clinical training and improve the quality of healthcare in developing countries. Two MTI doctors will complete their posts in 2024 and 3 in 2025. One MTI doctor was accepted for training in the UK during the period covered by this document and was interviewed via videoconference by an ENTUK executive representative and host trust representatives. The process of appointing a new MTI doctor has become increasingly complex so a guide has been produced to help people navigate the new process.

4. Mission statement:

To promote high standards in the training of specialists

Recruitment

National selection in 2024 remained online and 90 candidates were invited for interview on 11 and 12 March 2024 with 61 NTNs and two LATS successfully appointed to ST3 training. Quality assurance of the process was conducted. Following consultation with the AOT and SAC, the National Selection Committee has made some changes to the scoring system for ST3 applications in 2025 (subject to approval by MDRS/HEE). This is to encourage applicants to maximise their logbook numbers (which have remained lower) and recognise quality rather than quantity in audits/quality improvement projects, publications and presentations.

Specialty Advisory Committee (SAC)

A key relationship between educational committees and ENTUK is maintained by the President of ENTUK and the Director of Education sitting on the SAC, while SAC Chair Miss Ann-Louise McDermott is also a member of the ENTUK Executive Committee and the ENTUK Education and Training Committee. Her full report can be viewed in section 8 of the Annual Report.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 25

ANNUAL REPORT 2023 - 2024 ||

ENT Trauma course

This course has been developed to be tailored to ENT to replace the general ATLS but meet the GMC requirement of managing trauma patients. The first of the new ENT UK National Trauma Courses will be held in the next financial year, in Birmingham in November 2024 by course leads, Mr Paul Nankivell and Mr Josh Whittaker. It is run through ENTUK Enterprises Ltd.

Bootcamps

22 delegates registered for Leeds (24-25 October 2023) and 42 delegates registered for London (1-2 November 2023). The standardised feedback forms and certificates are issued and collated by ENT UK office. Going forward, the bootcamps will be run through ENTUK Enterprises Ltd.

5. Mission statement:

To represent the specialty at the Royal College of Surgeons

Fellowships

ENTUK provides support to the RCS Eng fellowship scheme by reviewing applications from teams who wish to provide a fellowship. In the last year, review and support of fellowship applications has been undertaken for The Royal National ENT Hospital Advanced rhinology and another for the UCLH Fellowship in Laryngology.

MRCS (ENT) Examination

Despite the ENTUK past-President and Director of Education, SAC chair, AOT president and co-chairs of the MRCS (ENT) presenting the benefit of MRCS (ENT) examination to ENT Trainees and the specialty, the ICBSE and the four Royal Colleges of the UK and in Ireland announced that the MRCS (ENT) examination is to be discontinued, subject to GMC approval. This was to ensure the summative assessment of candidates completing Core Surgical Training is consistent across all surgical specialties. The last sitting will be February 2026.

Final Notes

ENTUK has been responsive to concerns regarding Physician Associates (PAs) and the ENTUK President has discussed this with other members of FSSA. ENTUK has formed a PA Scope of Practice Working Group to support ENT doctors in training and define the appropriate roles of PAs in the safe provision of healthcare within the specialty. The work of the SFO Group (led by Mr Dheeraj Karamchandani) and the Community ENT Group is fundamental to the success of the education activity and reports on their activity can be found in section 9 of the Annual Report. ENTUK Education and Governance Officer, Ms Janet Stephen has provided outstanding support for all educational activities over the last year, and we would like to thank her for her contribution.

Miss Wendy Smith

ENTUK Director of Education

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

26

COVID

The effects of the pandemic on training show no real signs of recovery. Training in ENT continues with some procedures continuing to remain difficult to access in some regions. No Covid outcomes are remaining and there is an increase in outcome 3s as expected. Below is the latest logbook data released by JCST.

Curriculum

The first wave of proposed changes to the curriculum began in June 2024 and the proposals will hopefully be distributed to all stakeholders later this year. These proposals include the loss of sub-speciality interest in Phase 3 of training. All trainees would have an ST8 finish, and the accelerated route will remain for those who develop all their competencies sooner. Proposals for new index procedures

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

27

such as SPA ligation and paediatric tracheostomy are also included. The final timeline for this new curriculum is not yet known but hopes are that it will be ready by summer 2025.

Bootcamp and ENT Trauma course

These are continuing to be very successful and running at full capacity. ENTUK are working in partnership with SAC to provide both courses. The ENT Trauma course continues to evolve and encompass all the trauma and emergency aspects of Otolaryngology, and it will remain as mandatory on the curriculum (or ATLS).

National Selection

National selection Interviews remain on a virtual platform, and feedback from trainees has been very positive. Portfolio marking is now undertaken face-to-face with two examiners per portfolio.

The 2024/25 National Selection portfolio criteria has been changed to award marks for quality rather than quantity. Furthermore, there are additional marks awarded for more operative experience. All details can be found online.

Core Training

The MRCS examination is considered an exit examination for Core Surgical training. The MRCE(ENT) was perceived more as an “entry” examination into Otolaryngology. Furthermore, there was quite a substantial pass rate discrepancy between the two examinations. The ICBSE have now confirmed the end of the MRCS(ENT) with October 2024 being the last diet for new applicants. MRCS Parts A&B will be required for future National Selection and will be accepted for 2024/25 applications.

Workforce

Unfortunately, despite having an excellent meeting with the leads for NHSE and the four Royal Colleges in January 2024, there has been no further follow-up on workforce. Within our speciality, our trainee colleagues Ms Watts and Mr Lee continue to work on ensuring all our workforce data remains up to date and accurate.

Finally, this is my last report as SAC Chair as I am due to demit in December 2024. Currently, the interviews for the new SAC Chair are awaited.

I have thoroughly enjoyed my three years in office, and I am extremely grateful to all the SAC members who have worked so hard alongside me. It’s been a pleasure to get to know them all. Also, I would like to say a big thank you to everyone at ENTUK for all their support on many training matters during my tenure.

Miss Ann-Louise McDermott

Chair of SAC in Otorhinolaryngology

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

28

British Rhinology Society (BRS)

Our BRS and BRS Juniors membership continues to grow ‘year in and year out’ with record numbers at our annual 2024 meeting in Cardiff. Well done to Mr Ben Stew, our BRS Welsh representative Council Member, who organised the programme in collaboration with the Royal Society of Medicine travelling Professors. A special thank you to our platinum and gold sponsors; Medtronic and Stryker as well as Storz. Thank you to the BRS and BRSJ Councils as well as ENTUK in making this event such a success. The Dragon’s Den and poster presentations remain incredibly popular amongst our members, led by Mr Neil Tan. The Annual Meeting was in financial surplus but we had to cap face-to-face spaces as venue capacity was limited to 160 places. Virtual attendance was offered as a result of train strikes and to accommodate Hinari countries.

BRS continues to lead on teaching, research and inspiration across all domains of rhinology, with a future focus on standardising ‘rhinology patient pathways’ with respect to diagnostics, AI technology and sustainability at their core. We will continue to collaborate with NHS England and ENTUK to ensure rhinology is fully represented at a national level, orchestrated by Mr Yujay Ramakrishnan, our BRS Secretary, to whom we are very grateful. We have recently collaborated with BSFPS and ENTUK in creating guidelines and recommendations on ‘cocaine induced nasal vasculitis’ which are now on the ENTUK website. We are in the process of putting together guidelines on a minimum recommended requirements for provision of smell and taste clinics in collaboration with Fifth Sense.

Our Olympus sponsored ‘Advanced Rhinology Training’ fellowship continues to be a huge success, led by Ms Louise Melia. Our BRS mentorship programme for newly appointed rhinology consultants has been successfully launched led by Ms Archana Jaiswal.

I would like to say a big thank you to Mr Sam Leong our impressive Treasurer and Mr Henry Sharp and Mr Ben Stew for their diligent and committed tenureship on Council and wish them all the best for the future as they demit from Council. I would like to congratulate and welcome our new President-elect, Ashok Rokade.

I would also like to welcome Mr San Sunkaraneni, our new Treasurer, Mr Pranter Brahmabhatt our new Welsh Council member representative and Mr Annakan Navaratnam and Mr Oke Okonkwo as our new England representative Council members. I would also like to say a big thank you to Dr Vikas Acharya who is stepping down as President of the BRSJ and welcome to Mr Ed Balai as the new President and Dr Guled Jama as the new Vice President.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 29

ANNUAL REPORT 2023 - 2024 ||

BRS 2025 will be held in Edinburgh at the Royal College of Surgeons on 22 and 23 May 2025 which looks impressive and organised by Mr Iain Hathorn. We look forward to seeing you all there.

Prof. Peter Andrews

BRS President

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

30

British Society of Facial Plastic Surgery (BSFPS) *ABSFPS

It is just about six months, since I handed over my presidency to Prof. Anshul Sama, the current president of the British Society of Facial Plastic Surgery (BSFPS). I am delighted to see that our organisation has grown from strength to strength and continues to thrive, particularly in the education and training of future facial plastic surgeons. I would like to extend my congratulations to Anshul, who I am confident will lead BSFPS to even greater success. As planned, all council positions and regional representative roles have now been filled. We have also updated the BSFPS website, adding a new section dedicated to the organisation’s history and its past presidents. Our summer webinar series for 2024 was a resounding success, with an excellent line-up of well-received lectures. Additionally, we advertised two STORZ-funded BSFPS Travelling Fellowships for 2024. Following interviews, we selected two outstanding candidates, and we are optimistic that this fellowship will continue to be highly sought after in 2025 as well. The BSFPS dissection course in Nottingham, held from May 28th to 30th, 2024, was another grand success, with a waiting list of candidates eager to attend. Also, our podcast and coffee room chats, conducted by senior colleagues in collaboration with the Royal College of Surgeons of Edinburgh (RCSEd), have been uploaded to the RCSEd website and are now available for members to view. Looking ahead, the next BSFPS Annual Conference will be held on October 9-10 in Edinburgh, under the stewardship of Mr. Rohit Goel.

As we embrace the new year, I wish all BSFPS members and their families health, happiness, and prosperity. My heartfelt personal wishes to each of you.

Mr. Natarajan Balaji

Immediate Past-President, BSFPS

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

31

British Society of Otology (BSO)

The British Society of Otology has been very productive in the last 12 months and would first like to thank ENTUK for their support on many levels.

BSO Council meetings were held in November 2023 at the Royal Society of Medicine, London, and in March 2024 in Glasgow. On 14 March, Mr Owen Judd ran the annual Balance Course, which was followed by the first in-person BSO Juniors meeting.

The BSO Juniors Day was held in the fantastic Clinical Simulation Lab, at Kirkland’s Hospital and was organised by Mr Arun Iyer, ably supported by Lucy Dalton. Trainees were treated to a number of different virtual, synthetic and animal models to learn and practice ear surgery. There was a huge amount of industry sponsored equipment to use which was greatly appreciated by all.

The Balance Course was oversubscribed as usual and received fantastic feedback from all delegates. The Annual Meeting was held at the Royal College of Physicians and Surgeons of Glasgow also organised by Mr Arun Iyer. The programme was packed as was the beautiful and creaky lecture theatre in the College. There were sessions on the past, present and future of otology, free papers and finally a round table on the use of simulation in training otologists.

The baton of President of the Society was passed on from Professor Simon Lloyd who completed two years in the position to Mr Peter Monksfield. Two new members joined the BSO Council: Joe Manjaly and Charlie Huins.

We have continued to support research with small grants awarded as well as a larger £10,000 grant for a project to produce a novel bone conduction hearing device thereby achieving the goal set out in the document Budgetary Guiding Principles to spend the BSO surplus funds given to us by ENTUK.

We have worked on a national tympanoplasty electronic database available for all BSO members to use, which is complete and in a beta testing phase before being rolled out. We are very grateful for the financial help of ENTUK in producing this.

We have agreed to take over the organisation and awarding of the excellent Mr Matthew Yung and Professor Chris Raine Travelling Scholarship with no financial contribution from the BSO to this. We plan to award one/two of these per year to young consultant otologists to visit centres of otological excellence around the world for the next five years or as long as the funds will allow.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

32

We ran an online event on 14 September which was a joint collaboration with the American Otological Society (AOS) on the subject of wellness for otologists. The event included the current and past Presidents of the AOS, along with council members and the President of BSO. There were attendees from the UK and USA in addition to several other countries.

The event was recorded and will soon be available to watch again both on the AOS YouTube channel and on the ENTUK website.

Finally, guidance on the practice of microsuction has been written and will be published to guide all practitioners who undertake this treatment.

Mr Peter Monksfield

BSO President

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

33

Community ENT Group

The Community ENT Group has continued to meet virtually, and its membership is growing, consisting of a diverse group of clinical professionals including GPs, GPwER ENT, ENT Consultants, a Consultant Physiotherapist, and a Physician Associate. We also welcomed Dr Carla Harris to the Group as a GP Trainee Representative.

The Community ENT Group’s website page has been updated and includes links to relevant elefENT modules, patient leaflets and videos.

The Group continues to develop the elefENT resource to reflect the learning needs identified by the GPwER ENT curriculum. An e-learning module on Ototoxicity was submitted to elefENT, with ‘indications for tonsillectomy’, ‘radiology in ENT’, and ‘hearing and hearing aids’ currently in development.

In November 2023, ENT UK hosted a session at Guidelines Live attended by GPs, Pharmacists and other AHPs. It included an update on the management of tonsillitis, practical tips for managing rhinitis. Another session was also hosted on common ear conditions.

The Group is also currently engaged in improving the visibility and availability of primary care resources that have been developed to enable GPs to share these with patients in primary care. These include a leaflet on persistent throat symptoms and a video on vestibular migraine.

Dr Eason Sivayoham and Ms Wendy Smith

Co-Chairs of Community ENT Group

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

34

Head and Neck Society

We were delighted as a Society to see the publication of the 6th Edition of Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines in the JLO this year. This is a truly multidisciplinary set of guidelines which MDTs across the UK should find useful and ENTUK should be very proud of taking ownership of this important publication. All members of the Head and Neck Society have been extremely supportive of the publication, with many putting considerable time and effort into it for which we are very grateful.

Due to the Guidelines publication, we did not run the usual evidence-based meetings which are usually done on an annual basis. Instead, we plan to host two meetings in 2025, the first one in York on 14 March 2025 (sinonasal cancer) and then one in Newcastle on 21 November 2025. Planning and organising these meetings take much effort and we are confident that they will be successful meetings.

The Constitution of the society needed updating and ENTUK CEO Miss Katie Nurcombe has been helpful in driving this forward. We hope to have a new Constitution on the website by the end of the year. We also held voting for two new council members, and we are delighted to have Mrs Hannah Fox and Mr James O’Hara joining the Society. We thank Mr Ricard Simo for his hard work over the years who has been an outstanding contributor to the Society. As Professor Jarrod Homer continues to work as GIRFT ENT National Lead for Head & Neck Cancer, he will continue to attend meetings to provide invaluable feedback on the progress and outcomes of the GIRFT Review.

Mr Shane Lester stepped down as Secretary due to clinical pressures in his department and Mr Jai Manick has taken over this important role. Shane has been an excellent organiser and very helpfully will be staying on Council until his term ends. We are hoping to have more Council positions during the next year, and I was very pleased to see so many high-quality candidates applying for the previous positions. The Society needs to improve its presence and clarify its identity, and much work has been done on this in 2024 and will continue to be done.

Finally, the Treasurer reports that previous meetings have been profitable, and we have funds now to sponsor one or two ‘visiting fellows’ from underprivileged countries to visit head and neck units in the UK. The plan is for this to take place in 2025.

Mr Sanjai Sood

Head and Neck Society President

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

35

ENT Staff and Associate Specialists (SAS)

It was a great privilege to hold the post of SAS Chair between April 2023 and June 2024. Since starting the role, I have organised several webinars focused on SAS career progression. I have represented the SAS group in the ENTUK Council meetings and Educational Committee meetings. There have been contributions from the SAS Group to the ENT UK Foundation Research and Educational Grants.

The biggest achievement was organising the SAS Conference in Birmingham with the support of the ENTUK team. Conference attendance was good with active engagement of the group at various levels including the oral presentations. The Conference had eminent speakers in all aspects of ENT including topics on the Specialist Grade and the Portfolio Pathway 2024. The Conference was successful with positive feedback from the attendees.

Many of the SAS doctors are doing excellent work. Dr Amit Kochhar, Associate Specialist from Morecambe is the Deputy Chair, BMA representative body. He passionately represents SAS doctors with all external and internal stake holders. He has been involved in negotiating SAS pay conflict and believes in Equality and Diversity Inclusion.

Mr Urmil Chalishazar is the SAS advocate for his trust in South Wales. This is a senior leadership role in the board management. He is one of the members of ENTUK CPD Committee responsible for quality assurance of the ENT training courses in the UK. He is also an examiner for undergraduate students in Cardiff Medical School.

Mr Shyam Singam was nominated and went on to win the ‘Learning, Research and Development Award’ at South Devon Healthcare Trust in October 2023. For his contributions to ENTUK, he was granted ENTUK Honorary Membership at the ENTUK April Spring Meeting in Edinburgh.

Mr Kannan Ramachandran and Mr Shyam Singam are Committee members of the SAS Group. They actively contributed to organising the SAS Conference. Dr Umesh Nagalotimath won the prize for the oral presentation at the SAS Conference for his presentation on the Thermal effects of electric cautery – visual demonstration.

Mr Swaminathan Ramanathan SAS Chair

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 36

ANNUAL REPORT 2023 - 2024 ||

Student and Foundation Doctors in Otolaryngology (SFO UK) LASFOUK

The SFO group has continued to support the training and development of medical students and foundation doctors in alignment with the ENT UK strategy. Since its inception, membership has grown significantly—from 40 members in 2016 to 526 at the time of writing. We hope to sustain this momentum and translate it into a vibrant future for the specialty by inspiring the next generation of ENT surgeons.

Over the past year, we have been working on an update to the SFO E-Book, a key resource informed by undergraduate leads, which is now recognised as a core text in many medical schools. We aim to complete this revision by the end of 2025 to ensure its continued relevance and utility for medical students.

In addition, we have been making preparations for the SFO Day at BACO 2026 and the SFO Annual Conference 2025, which will feature a diverse range of talks and high-fidelity skill stations. The ENT UK Undergraduate Essay Prize, a longstanding tradition dating back to 1981, continues to attract a large number of high-quality submissions, reflecting the sustained enthusiasm for ENT among medical students.

This year, we have also planned a new webinar series featuring expert-led discussions aimed at medical students and junior doctors. The first session is scheduled for February 2025, and we anticipate it will become a valuable addition to our educational offerings, complementing our existing in-person events and conferences.

A new cohort of SFO representatives was appointed in September 2024, following a highly competitive selection process. Our regional representatives have continued to organise a variety of outreach events across the UK to promote ENT as a career choice and highlight the educational and professional support available through ENT UK.

Looking ahead, SFO UK remains committed to expanding educational opportunities, strengthening mentorship pathways, and further enhancing engagement with aspiring ENT professionals.

Mr Dheeraj Karamchandani Chair, SFO UK

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

37

Young Consultants in Otolaryngology and Head and Neck Surgery (YCOHNS) - (gens

Since the last update, we have had some changes to the Young Consultants in Otolaryngology and Head and Neck Surgery Committee. Ms Nina Mistry and Ms Sevie Tzortzis have been recently appointed a Co-Chairs sharing the role of YCOHNS President. Whilst they settle into their new roles, Mr James Barraclough will remain as Past President. Mr Dheeraj Karamchandani continues as Treasurer. Links with the Association of Otorhinolaryngologists in Training are continuing with Miss Tharsika Myuran as our AOT liaison representative. We still have vacant roles on the Committee, including Secretary and Social media representative, so if you'd like to be involved, please get in touch.

In November 2023, we held the highly successful YCOHNS relaunch event. The event attracted young consultants and senior trainees from all over the country. The meeting generated plenty of discussion on important issues surrounding life as a new consultant, with valuable insight into taking on roles in medical leadership and management. The conference allowed members to network and socialise and reminded us of the importance of face-to-face meetings following on from the pandemic. It was also great to see that there is still a huge appetite from our members for more YCOHNS events.

This brings us on to the exciting news of our upcoming event in June 2025. The event will include an evening of networking and socialising. There will be talks from exceptional speakers on topics ranging from job planning, education, leadership and management, to getting started in private practice, innovation and mental health and well-being. It promises to be an interesting and informative event and essential for ENT consultants within five years of appointment, senior trainees and post-CCT Fellows. We look forward to seeing you there!

Ms Nina Mistry, Ms Sevie Tzortzis YCOHNS Co-Chairs

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

38

The British Otorhinolaryngology and Allied Sciences Research Society (BOARS)

BOARS aims to provide a forum for the best current research in ENT, Hearing and Balance in the UK. Two meetings are held each year that combine oral presentations with research education for academic trainees.

BOARS took part in the annual ENTUK Research Showcase Meeting, which was held in conjunction with the Foundation Research and Education Awards. This meeting was very well attended and hosted the hustings for the new president. The Angel James Prize was awarded to Miss Sumrit Bola for her work on circulating DNA in the follow-up of head and neck cancer patients. The poster prize was awarded to Miss Madeline Gadd, with the junior prize going to Miss Marina Forbes.

The Spring Meeting was held online. This was to attempt to increase engagement from across the ENT research community. Around 10 trainees presented their work, and the Philip Stell Prize was awarded to Mr Amar Rajgor for his work looking at the role of radiomics in the prognostication of laryngeal cancer. The afternoon of this meeting was dedicated to a research prioritisation exercise. Participants were divided into four groups: rhinology, otology, paediatrics, and head and neck. Each group was chaired by a senior academic in the field and the findings were presented to, and discussed, as a group at the conclusion of the meeting.

Mr David Hamilton

BOARS Secretary and President-elect

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

39

British Society for the History of ENT (BSHENT) \BSHENT

The Annual Meeting of the British Society for the History of ENT was held in the Toynbee Mackenzie ENT Room at the Royal Society of Medicine on Thursday 30 November 2023. The room was filled with history enthusiasts ranging from foundation trainees to retired professors. Over 30 papers were submitted, from which 12 were chosen for presentation. An additional presentation entitled ‘Can we illustrate the history of otology with caricatures and cartoons: A methodological question? Was given by Professor Albert Mudry from Lausanne, Switzerland.

The Journal of Laryngology and Otology (JLO) prize for the best junior presentation was won by Dr Vikash Dodhia for his paper entitled ‘Dogs, an icepick, and an electric razor: The history of voice prosthesis and symbiotic relationship between resection and restoration’. Ms Ying Ki Lee was a close runner-up with his paper ‘Between Myth and Medicine: Goitre in Ancient Chinese History’.

The afternoon concluded with an AGM. The three chairs of the meeting—Mr Richard Irving, Miss Emma Stapleton, and Mr Neil Weir—were re-elected to the BSHENT committee, along with Mr Edward Fisher, who chaired the judging panel, and Ms Katherine Conroy.

The next annual meeting will be on Thursday 5 December 2024.

Mr Neil Weir

BSHENT President

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

40

Global Health Committee

It has been a busy time over the past 12 months for the Global Health Committee. We have been working on a number of new and ongoing Global Health initiatives.

The Global Health Committee are stakeholders at the World Hearing Forum established by the WHO. This is a global network of stakeholders that promote ear and hearing care worldwide. Mr Oyeleye Oyelakin has taken up the role of representing the committee and is doing an excellent job!

We continue to run our grant scheme. Grants are awarded to health professionals and non-governmental organisations involved in ENT-related initiatives. The projects must demonstrate sustainability in areas of greatest need.

The Guidelines Project (in collaboration with Global OHNS) continues to develop. This is a project aimed at providing free, evidence-based guidelines catering for the large variation in resources available in various global healthcare settings. It is on the ENTUK resources webpage.

Ms Catherine de Cates and Mr Aurelien Gueroult from the Committee have taken on the challenging subject of equipment donation and sustainability in lowresource settings. They have written an excellent article on the subject with Mr Gan-Erdene Narantsolmon from Mongolia, which has recently been published in Current Opinion in Otolaryngology and Head & Neck Surgery. More recently, we have met with and intend to work with Mr Tim Beacon from Medical Aid International, an excellent organisation that provides hardware support to surgical services around the world.

The Committee is sometimes asked to support and develop ENT services. A request came from the Zambia ENT, Audiology and Speech Therapy Society to support their services. Mr Matthew Clark and a team of otologists went to Zambia earlier this year. It is a country of just under 20 million people with only five ENT specialists. Matt and his team managed to run a temporal bone course and a practical ENT course for 80 students, doctors, nurses and audiologists. They were accompanied by two UK medical students who were able to conduct research into telemedicine and otoscopy. This type of initiative represents an ongoing collaboration which will see concrete advances in delivering ENT care in a lowincome country. In the past month, we have been asked to facilitate introducing skull base surgery into Mongolia and I will report back on this next year.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

41

Miss Emma Stapleton from the Committee had a successful trip to Uganda supported by a Global Health Committee grant, setting up a small hearing health clinic in the education sector in rural Jinja. Working in the education sector can be an advantage in terms of picking up deafness and then being able to follow up with patients reliably.

In terms of working with other specialties, we are part of an initiative organised by Professor Chris Lavy at the Royal College of Surgeons of England to work with and learn from other global health specialty groups.

Our annual virtual conference in November was considered a success. We were fortunate enough to have fantastic speakers from around the world speaking on a variety of interesting and challenging topics. We also had a free papers section with a prize for the best paper.

Mr Nick Eynon-Lewis

Chair ENT UK Global Health Committee

----- Start of picture text -----
BACK TO THE
TABLE OF CONTENTS
----- End of picture text -----

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

42

Private Practice Committee

We have mainly engaged in the private practice area via our engagement with FIPO (Federation of Independent Practitioner Organisations), that a number of Specialty Association private practice representatives attend. Issues raised at FIPO, which have remained similar have included:

The BMA Private Practice Committee have also become more active in recent years and are also actively looking at these issues. One area of concern has been the impact of referral management by private insurers utilising subjective criteria, which is not in the public domain, to direct referrals to specific groups of consultants. They have also mooted a proposal for setting up an independent company, BMA Health, to support consultants and provide a variety of services and support. We will update members as more details become public.

Engagement with FIPO and BMA is likely the main routes to address the concern many members have with fees especially as the private medical insurers have no interest in discussing with individual specialty assoications.

We have also engaged with PHIN (Private Healthcare Information Network) and some issue of relevance include:

We continue to receive concerns from colleagues about fees paid by private medical insurers (PMI) remaining stagnant for many years and not taking account of rising costs.

BUPA have recently changed their algorithm for calculating fees with a supposed uplift. This will look at a number of factors including time (including pre and postoperative time), complexity, specialist training. ENTUK was invited to an update on the new model but there was no opportunity to provide any feedback or concerns about the model. There was no opportunity to also assess the accuracy of the data used to generate the new fees.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 43

ANNUAL REPORT 2023 - 2024 ||

We will continue to raise important issues at ENTUK Council. Please contact via ENTUK if you would like any issues to be raised. We are unable to directly help with individual queries but can signpost to the relevant organisations that can help.

Mr Ram Moorthy

Private Practice Committee Chair

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

44

Women in ENT Surgery (WENTS UK)

This year WENTS UK has been focussing on women in leadership, with a series of webinars and the launch of our first Leadership Course.

Three webinars have been held over the past year, facilitated by ENTUK. Attendance was excellent (not restricted to women) from ENTUK members and non-members alike, and we had engagement from participants not just from other specialties but other professions. We hosted:

The Leadership Course was run at RCS England in May, led by our WENTS Secretary Ms Marie Lyons, an experienced trainer in leadership. The course was organised and facilitated by WENTS Co-President Miss Anna Slovick, funded by the Andrew Foster Leadership Grant from the ENTUK Foundation which she was awarded on behalf of WENTS. Delegates of all genders and career stages participated in open and supportive discourse on various aspects of leadership, and feedback was excellent. We are planning to run the course again in 2025.

Aside from leadership themes, the WENTS and Friends podcast has had over a thousand downloads across thirty-four countries, reaching number thirty-six in the UK medical podcast chart. Discussions on training, menopause, and pregnancy proved particularly popular with listeners. Thanks to funding from the ENTUK Foundation and sponsorship from Storz, six more podcast episodes have been outlined and will proceed to production.

On International Women’s Day (IWD), we opened applications for the Shyamala Educational Grant, generously funded by the ENTUK Foundation. Awards of £500 each were made to Dr Alex Ashman and Miss Isabelle Williams for their projects centring the IWD 2024 message ‘Inspire Inclusion’. Applications will open again in March 2025.

The coming year, we will see three more WENTS webinars, this time with the theme of research. Dates are yet to be confirmed, but our first guest will be renowned speaker, surgeon, and researcher in diversity and inclusion, Dr Arghavan Salles. She will be discussing her well-publicised JAMA paper on the

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

45

relationship between surgeon sex and postoperative outcomes – and why a deep dive into the data can make us all better surgeons.

For information on upcoming podcasts, courses, grants and webinars, look out for announcements in the ENTUK Newsletter or sign up to become a member of WENTS UK (all genders welcome!). You can also follow us on X (Twitter), Threads, LinkedIn, and Instagram – see our page on the ENTUK website for more details.

The WENTS UK Committee would like to express our appreciation for the continued support of our members, the ENTUK Foundation, the wider ENTUK community, all our collaborators and sponsors, and everyone who has attended or participated in our activities of the past year. We are very much looking forward to the year ahead!

WENTS UK Executive Committee

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

46

(I. FINANCIAL REVIEW Overview of ENTUK finances: period 2023-2024

Introduction

This report covers the financial year from October 1, 2023, to September 30, 2024.

The turnover for the year, excluding gains on investments, was £938,967, down from £1.73 million last year. Total expenditure for the year was £857,750, down from £1.4 million last year. Expenditure for last year was high because of cost associated with organising BACO2023.

Main activities

1. Membership activities

Membership income remains key source of income for the Association.

Membership revenue increased to £499,574 from £484,000. Total paying membership headcount on 30 September 2024 was 2,337.

Total expenditure for running the membership support and the office was £593,320. Expenditure included Office staff cost, IT, rent, professional fees etc. of this, staff cost for the year was £41,810.

2. Events and Courses

Events generated £201,425, down from £897,030 last year, again due to BACO's absence.

The direct cost of organizing the events throughout the year, excluding staff costs, was £111,050. All events were well attended by members.

3. Product and Marketing Income

Product income of £11,421 includes income from Course accreditation, MTI placements, e-lefent income. Marketing services income remained unchanged at £15,000.

4. Donation income and grants payments

The ENTUK Foundation secured £52,449 in donations, matching last year's total. This funding supports research and collaborations in ENT.

BSO and Global Health received total of £10,000 in donations from private donors.

The ST3 Bootcamp joined ENTUK on October 1, 2023, bringing with them £42,468 in cash. This fund has been designated for expenditure related to ST3 Bootcamps. This is an accounting adjustment and not a donation.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 47

ANNUAL REPORT 2023 - 2024 ||

During the financial year, ENTUK and its sub-groups spent £95,640 to fund fellowships and strategic projects through designated funds. Grants awarded from ENTUK's strategic reserve during the year include:

5. Administrative Services

We provided administrative services to The TWJ Foundation for £4,500.

6. Cash and Investment portfolio

Total cash at bank on 30 September 2024 (including cash held in investment portfolio controlled by Brewin Dolphin) was £1.29m up from £1.09m last year. Total value of the investment portfolio on 30 September 2024 was £2.64m (£2.48m in stocks and rest in cash including cash held in investment account). The value of the Investment on 30 September 2023 was £2.40m (£2.37 in stock and rest in cash held in investment account).

Dividend income for the year was £55,503, and interest income was £45,210. Interest income was from the cash held in CCLA Charity deposit fund which pays higher interest rate. As the interest rate in the UK falls, we anticipate that future interest income will fall in line with interest rate.

Furthermore, £54,000 was withdrawn from the investment portfolio during the year as a part of the strategic reserve review to help fund critical initiatives for the broader benefit of our members and patients. Over the past year, we have withdrawn £150,000 from the portfolio to spend on a variety of strategic projects such as Head and Neck cancer feasibility study, and RCS leadership projects.

Summary

The total surplus for the year as per the audited account for 2023-24 was £393,663 which includes gain of £315,166 from investment portfolio revaluation.

Please note that the Investment gain is a statutory accounting adjustment rather than actual surplus for the year. So, total statutory surplus (before Gain on investment) was £78,497. This surplus is made up £42,468 ST3 Bootcamp cash, £9,497 on unspent cash raised by subgroups holding funds under designated activities and £29,282 from actual operating activities during the year.

This figure of 29,282 figure is in line with the aim of ENTUK which seeks to operate at least at breakeven level on its day-to-day operating activities for long term sustainability.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

48

Balance Sheet

As of September 30, the total value of ENTUK's balance sheet was £3.78 million compared to £3.38 million last year.

Financial Outlook

Each year brings new challenges for ENTUK. The Trustees remain committed to keeping ENTUK on a sustainable path while supporting ENT patients and clinicians across the UK, in line with our charitable mission.

Considering the impact of rising inflation and the challenging financial environment for our members, we have reduced consultant membership fees by 12% and frozen fees for other membership grades until 2027. We continually listen to our members and appreciate their continued support for ENTUK, ensuring it remains a vital organization representing the ENT subspecialty.

ENTUK has successfully launched a wholly owned trading subsidiary, ENTUK Enterprises LTD, designed to streamline the organization of our events, including BACO, while also exploring various commercial opportunities that were previously unattainable for fundraising through the charity. To ensure efficiency and collaboration, a formal resource-sharing agreement is in place, guaranteeing that all profits generated will be donated directly to ENTUK.

ENTUK Enterprises LTD was formally registered with Companies House in April 2024 and began full operations from October 1, 2024. It operates under a dedicated Board of Directors, with the Finance Committee and Trustees of ENTUK providing essential oversight over its operations.Financial Outlook

Reserves policy

What are Reserves

Reserves refer to the portion of a charity’s unrestricted funds that are available for spending on any of the charity's purposes. To calculate the reserves held by a charity, one must start with the total amount of unrestricted funds. However, some or all of these unrestricted funds may not be readily available for spending. This limitation is typically due to concerns that using these funds might negatively impact the charity's ability to achieve its objectives. Funds that should be excluded from reserves include: tangible fixed assets used to carry out the charity’s activities, such as land and buildings.

Purpose

The Reserves Policy for ENT UK aims to ensure the stability of the association's mission, programs, employment, and ongoing operations. It also serves to provide internal funding for organizational priorities.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

49

This Reserves Policy will be implemented alongside other governance and financial policies of ENT UK and is intended to support the goals and strategies outlined in these related policies as well as in ENT UK’s strategic and operational plans.

There will be two types of reserves:

Operating Reserve

The Operating Reserve is designated for funding the day-to-day operational costs and for covering any in-year actual or projected deficits. This reserve serves as an internal funding source for situations such as covering deficits from budgeted strategic loss-making activities, unexpected increases in expenses, one-time unbudgeted expenses, unanticipated funding losses, or uninsured losses, including redundancy costs and significant financial commitments.

The Operating Reserve is not meant to replace a permanent loss of funds or to eliminate an ongoing budget gap.

The fund is defined as a designated reserve set aside by a decision of the Board of Trustees based on a recommendation from the Finance Committee. The minimum amount designated as the Operating Reserve will be established to ensure the continuity of operations and programs for a defined period, typically measured in annual costs.

The Operating Reserve plays a dynamic role and will be reviewed and adjusted in response to both internal and external changes. The target current minimum for the Operating Reserve Fund will be calculated based on 9 months of operating costs.

The calculation of average annual operating costs includes all recurring, predictable expenses such as staff salaries and benefits, occupancy, office expenses, travel, program costs, and ongoing professional services. Non-cash expenses, such as depreciation and benefit-in-kind, are excluded from this calculation, as are expenses related to restricted funds, capital expenditures, and partner payments.

The target minimum amount for the Operating Reserve Fund will be calculated each year after the approval of the annual budget, reported to the Finance Committee and Board of Trustees, and included in regular financial reports.

Opportunity Reserve

The Opportunity Reserve provides funding for activities that help achieve the charity’s objectives but are not deemed essential. This reserve is intended to support special opportunities or needs that further the goals of ENT UK, which may or may not lead to increased income in the short- or long-term.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

50

The Opportunity Reserve can also fund organizational capacity-building initiatives, such as research and development, membership growth, staff training, or investments in infrastructure that enhance long-term capacity.

This reserve is expected to be allocated based on a 5-year projection of need and should be frequently used, monitored, and replenished from the unrestricted reserve.

Large legacies will be allocated to this reserve so that their use can be designated for specific projects, minimizing their absorption into general overhead costs.

The target amount for the Opportunity Reserve will be determined annually by the Board, based on recommendations from the Finance Committee and considering factors such as:

Accounting of Reserves

Designated or ring-fenced funds are not included in the calculation of reserves.

Reserves will be reported to the Finance Committee on a quarterly basis.

Funding of Reserves

The Operating Reserve will be established using surplus unrestricted operating funds, ensuring a solid financial foundation for our initiatives.

The Board of Trustees is empowered to identify specific revenue sources that can be dedicated to the Operating Reserve. This could include one-time generous gifts, bequests, special grants, or unique fundraising efforts. By proactively setting funds aside, we can enhance our capacity to respond to pressing needs.

The Opportunity Reserve will be supported by occasional special designations from the Board of Trustees, as well as through significant legacies that are not earmarked for the ENT UK Foundation. This strategic funding approach allows us to seize opportunities as they arise.

Use of Reserves

1. Identification of appropriate use of Opportunity Reserve

Utilization of the Opportunity Reserve must be reserved for projects that are in complete alignment with the ENT UK Strategy. Each project should present a compelling rationale for investment, ideally supported by a comprehensive Business Case that outlines clear and measurable outcomes.

2. Authority to utilise Opportunity Reserve Funds

Any withdrawal of funds from the Opportunity Reserve must receive discussion and approval from our Trustees. It is preferred that requests for the use of these

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

51

funds are brought forward in advance of the financial year during the budgetsetting phase. Nevertheless, we remain flexible; requests can also be considered throughout the year if unallocated funds are accessible, ensuring we remain agile in our response.

3. Reporting and monitoring

All decisions regarding spending must be formally recorded in the minutes of the Board of Trustees. Additionally, any withdrawals from the reserve, along with funding commitments, will be transparently reported in our quarterly financial statements, maintaining accountability and trust.

Review of Policy

This policy will be reviewed at least once a year by the Finance Committee, or more frequently if necessary due to internal or external events or changes. The Finance Committee will recommend any changes to the policy to the Board of Trustees.

Statement on Reserves

The total value of ENTUK’s balance sheet on 1[st] October 2024 was £3.8m up from £3.4m on 1[st] October 2023.

In the 2023-24 financial year, the Trustees of ENTUK under the recommendation of the Finance Committee have agreed to revise the Reserves Policy. This policy revision was made to:

This process identified that it would be financially prudent to set reserve that is equivalent to 9 months of operating expenditure. In doing so, ENTUK have unlocked potential funds that can be used to fund major projects that can benefit the membership. For the time being, the annual drawing of £50k from the investment portfolio will continue until further notice. The Trustees of ENTUK have voted to create an Opportunity Reserve fund that should be used to support strategic projects.

This policy will be reviewed at least annually to ensure the level of reserves being maintained is at the optimum level.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

52

Statement of Trustees’ responsibilities

The Trustees (who are also directors of ENTUK for the purposes of company law) are responsible for preparing the annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

The trustees’ annual report was approved on 8 May 2025 and signed on behalf of the board of trustees by:

Miss Helen Cocks President of ENTUK

Mr Andrew Kinshuck

ENTUK Honorary Treasurer

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

53

ENTUK

formally known as ENT UK trading as British Academic Conference in Otolaryngology (BACO) and British Association of Otorhinolaryngology - Head and Neck Surgery (BAO-HNS)

(A company limited by guarantee)

Annual Report and Financial Statements for the Year Ended 30 September 2024

Contents

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

54

Reference and Administrative Details

Trustees

Secretary

Senior Management

----- Start of picture text -----
BACK TO THE
TABLE OF CONTENTS
----- End of picture text -----

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

55

Registered Office

38-43 Lincoln's Inn Fields London WC2A 3PE The charitable company is incorporated in England & Wales.

Charity number

1125524

Company Registration Number

6452601

Solicitors

SA Law 60 London Road St Albans Hertfordshire AL1 1NG

Bankers

National Westminster Bank Plc

Bloomsbury Parr's PO Box 158 214 High Holborn London WC1V 7BX

Auditor

Edmund Carr LLP Chartered Accountants & Statutory Auditor 146 New London Road Chelmsford Essex CM2 0AW

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

56

Independent Auditor's Report to the Members of ENTUK

Opinion

We have audited the financial statements of ENTUK (the 'charitable company') for the year ended 30 September 2024, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

57

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by

exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

58

small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the Statement of Trustees's Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows;

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

59

We assessed the susceptibility of the company’s financial statements to material misstatement, including obtaining an understanding of how fraud might occur by:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

60

We communicate with those charged with governance regarding the planned scope and timing of the audit and significant audit findings, including any deficiencies in internal control we identify during our audit.

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its trustees as a body, for our audit work, for this report, or for the opinions we have formed.

S Morrell

Sandra Morrell FCCA (Senior Statutory Auditor)

For and on behalf of Edmund Carr LLP, Statutory Auditor

146 New London Road, Chelmsford, Essex, CM2 0AW

Date:............................. 22 May 2025

----- Start of picture text -----
BACK TO THE
TABLE OF CONTENTS
----- End of picture text -----

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

61

Statement of Financial Activities for the Year Ended 30 September 2024

(Including Income and Expenditure Account and Other Comprehensive Income)

Note
Total 2024(£)
Total 2023(£)
~~—~~		 Note
Total 2024(£)
Total 2023(£)
~~—~~		 Note
Total 2024(£)
Total 2023(£)
~~—~~		 Note
Total 2024(£)
Total 2023(£)
~~—~~
Income from:
~~—~~		 ~~—~~ ~~—~~ ~~—~~
Charitable activities
~~—~~		 3
~~—~~		 838,254
~~—~~		 838,254
1,654,392
~~—~~
Investment income
~~a~~		 4
~~a~~		 100,713
~~a~~		 713
80,460
~~a~~
Total income
~~a~~		 ~~a~~ 938,967
~~a~~		 938,967
1,734,852
~~a~~
Expenditure on:
~~a~~
 ~~a~~
 ~~a~~
 ~~a~~
Raisingfunds
 5
 13,645
 13,645
12,523
Charitable activities

~~ee~~		 6

~~ee oe~~		 846,825

~~oe~~		 825
1,405,529
Total expenditure
~~a~~
~~ee~~		 ~~a~~
~~ee oe~~		 860,470
~~a~~
~~oe~~		 860,470
1,418,052
~~a~~
Net income before investmentgains
~~a~~
~~ee~~		 ~~a~~
~~ee oe~~		 78,497
~~a~~
~~oe~~		 497
316,800
~~a~~
Gains/losses on investment assets
~~a~~
~~ee ~~
~~ee~~		 ~~a~~
~~ee oe~~
~~ee~~		 315,166
~~a~~
~~oe~~		 315,166
74,678
~~a~~
Net income
~~a~~
~~ee~~		 ~~a~~
~~ee~~		 393,663
~~a~~		 663
391,478
~~a~~
Net movement in funds
~~a~~
~~ee~~
~~ee~~		 ~~a~~
~~ee~~
~~ee~~		 393,663
~~a~~
~~ee~~		 393,663
391,478
~~a~~
~~ee~~
Reconciliation of funds
~~ee~~
~~		 ~~
~~a~~		 ~~ee~~
~~		 ~~
~~a~~
Total funds brought forward
~~a~~		 ~~a~~ 3,384,712
~~a~~		 3,384,712
2,993,234
~~a
Total funds carried forward
~~a~~		 19
~~a~~		 3,778,375
~~a~~		 375
3,384,712
~~a~~

All of the charitable company's activities derive from continuing operations during the above two periods.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

62

Balance Sheet as at 30 September 2024

Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)
Fixed assets
Intangible assets 11 40,072 40,072
-
Tangible assets
~~a~~		 12
~~a~~		 41,825
~~a~~		 825
40,979
~~a~~
Investments
~~a~~		 13
~~a~~		 2,482,890
~~a~~		 2,482,890
2,368,086
~~a~~
~~ee~~ ~~ee~~ 2,564,787 787
2,409,065
Current assets
~~ee~~		 ~~ee~~
Debtors 14 134,429 429
69,552
Cash at bank and in hand
~~a~~		 15
~~a~~		 1,288,646
~~a~~		 1,288,646
1,087,601
~~a~~
~~a~~ ~~a~~ 1,423,075
~~a~~		 075
1,157,153
~~a~~
Creditors: Amounts falling due within oneyear
~~a~~
~~pT~~		 16
~~a~~
~~pT~~		 (209,487)
~~a~~
~~pT~~		 (209,487)
(181,506)
~~a~~
~~pT~~
Net currentassets
~~pT~~		 ~~pT~~ 1,213,588
~~pT~~		 588
975,647
~~pT~~
Net assets 3,778,375 3,778,375
3,384,712
**Funds of the charitable company: **
Unrestricted income funds
Unrestricted funds 3,778,375 375
3,384,712
Total funds
~~Po~~		 19 3,778,375 3,778,375
3,384,712

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The financial statements on pages 62 to 79 were approved by the trustees, and authorised for issue on 08/05/2025 and signed on their behalf by:

A Kinshuck, Honorary Treasurer & Trustee

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

63

Statement of Cash Flows

for the Year Ended 30 September 2024

Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)		 Note
2024(£)
2023(£)
Cash flows from operating activities
Net movement in funds
~~-~~		 ~~-~~ 393,663 393,663
391,478
Adjustments to cash flows from non-cash items
~~-~~		 ~~-~~
Depreciation
~~-~~		 12
~~-~~		 13,428 13,428
12,638
Investment income
~~-~~		 4
~~-~~		 (100,713) (80,460)
Unrealisedgains/losses on investment assets
~~-~~
~~		 ~~ 13
~~-~~
~~		 ~~
~~ ~~
~~
Working capital adjustments
~~		 ~~
(Increase)/decrease in debtors 14 (64,877) 364,149
Increase/(decrease) in creditors 16 23,606 23,606
(57,833)
Increase/(decrease)in deferred income 4,375 375
(190,947)
Net cash flows from operatingactivities (3,099) (3,099)
382,275
Cash flows from investing activities
Interest receivable and similar income 4 45,210 45,210
26,402
Purchase of intangible fixed assets 11 (40,072) -
Purchase of tangible fixed assets 12 (14,274) (14,274)
(1,372)
Purchase of investments 13 (325,292) (258,226)
Sale of investments 483,069 483,069
292,098
Income from dividends 4 55,503 503
54,058
Net cash flows from investingactivities 204,144 204,144
112,960
Net increase in cash and cash equivalents 201,045 045
495,235
Cash and cash equivalents at 1 October 1,087,601 1,087,601
592,366
Cash and cash equivalents at 30 September 1,288,646 646
1,087,601

All of the cash flows are derived from continuing operations during the above two periods.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

64

Notes to the Financial Statements

for the Year Ended 30 September 2024

1. Charitable company status

The charitable company is limited by guarantee, incorporated in England & Wales, and consequently does not have share capital. Each member is liable to contribute an amount not exceeding £1 towards the assets of the charitable company in the event of liquidation.

2. Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

ENTUK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charitable company.

Exemption from preparing group accounts

Consolidated group accounts have not been prepared on the basis that the subsidiary is considered to be immaterial.

Income and endowments

Donations and legacies

General donations and other similar types of voluntary income are brought into account when receivable and donated income is included gross of any

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

65

attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income.

Deferred income

Deferred income relates to conference attendance fees and exhibitor fees received for conferences due to take place after the year end.

Investment income

Investment income is accounted for on a receivable basis once the dividend or interest has been declared.

Charitable activities

Subscriptions

Subscriptions are accounted for on a receivable basis, with the exception of life subscriptions that are recognised as income in full in the period in which they are received.

Other income

All other types of income are accounted for on an accruals basis.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.

All resources expended are inclusive of irrecoverable VAT.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grant expenditure

Grants payable are recognised in the period in which the approved offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised only when the conditions attaching to the award are fulfilled. Grants offered subject to conditions, which have not been met at the balance sheet date, are noted as a potential commitment, but are not treated as a liability.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

66

Grant provisions

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Taxation

The charitable company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charitable company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Intangible assets

Intangible assets are stated in the Balance Sheet at cost less accumulated amortisation and impairment. They are amortised on a straight line basis over their estimated useful lives.

Tangible fixed assets

Individual fixed assets costing £1,000 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated . impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class
Depreciation method and rate		 Asset class
Depreciation method and rate
Office refurbishment Over 5years,straight-line
Computers Over 4years, straight-line
Office equipment Over 5years,straight-line

Fixed asset investments

Fixed asset investments are included at market value at the balance sheet date. Realised gains and losses on investments are calculated as the difference between sales proceeds and their market value at the start of the year, or their subsequent cost, and are charged or credited to the Statement of Financial Activities in the period of disposal.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

67

Unrealised gains and losses represent the movement in market values during the year and are credited or charged to the Statement of Financial Activities based on the market value at the year end.

Trade debtors

Trade debtors are amounts due from members and delegates for subscription and conference fees.

Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the Association will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, deposits and cash balances held by investment managers.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the Association does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised at the transaction price.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the Association. Designated funds are unrestricted funds set aside for specific purposes at the discretion of the trustees.

Pensions and other post retirement obligations

The charitable company participates in the Superannuation Arrangements of the University of London (SAUL), which is a centralised defined benefit scheme and is contracted-out of the Second State Pension. SAUL is a "last man standing" scheme so that in the event of the insolvency of any of the participating employers in SAUL, the amount of any pension funding shortfall (which cannot otherwise be recovered) in respect of that employer will be spread across the remaining participant employers and reflected in the next actuarial valuation. A formal valuation of SAUL is carried out every three years by professionally qualified and independent actuaries using the Projected Unit method. Informal reviews of SAUL's position are carried out between formal valuations.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

68

3. Income from charitable activities

Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2024 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2024 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2024 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2024 (£)
Subscription income from members 499,574 574
-		 -
499,574
Meetingand conference income 201,425 201,425
-		 -
201,425
ENT UKproduct income 11,421 421
-		 -
11,421
Marketingservices Income 15,000 15,000
-		 -
15,000
Other income
~~ee~~		 110,834 834
-		 -
110,834
~~ee~~
~~a~~		 838,254
~~a~~
~~a~~		 838,254
-
~~a~~		 -
838,254
~~a~~
Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2023 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2023 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2023 (£)		 Unrestricted
Funds(£)
Restricted
Funds(£)
Total 2023 (£)
Subscription income from members
 484,309
Meetingand conference income
 897,030
ENT UKproduct income 12,539 539
-		 -
12,539
Marketingservices Income 8,300 8,300
-		 -
8,300
Other income 252,214 214
-		 -
252,214
1,654,392 1,654,392
-		 -
1,654,392

4. Investment income

Unrestricted
funds(£)
Restricted
Funds(£)
Total 2024 (£)
Total 2023 (£)		 Unrestricted
funds(£)
Restricted
Funds(£)
Total 2024 (£)
Total 2023 (£)		 Unrestricted
funds(£)
Restricted
Funds(£)
Total 2024 (£)
Total 2023 (£)		 Unrestricted
funds(£)
Restricted
Funds(£)
Total 2024 (£)
Total 2023 (£)		 Unrestricted
funds(£)
Restricted
Funds(£)
Total 2024 (£)
Total 2023 (£)
Income from listed
investments		 55,503 55,503
-		 -
55,503		 55,503
54,058
Interest receivable on
bank deposits		 45,210 45,210
-		 -
45,210		 45,210
26,402
100,713 100,713
-		 -
100,713		 100,713
80,460

5. Expenditure on raising funds

Investment management costs

Note
Unrestricted
funds(£)
Restricted
funds(£)
Total funds (£)		 Note
Unrestricted
funds(£)
Restricted
funds(£)
Total funds (£)		 Note
Unrestricted
funds(£)
Restricted
funds(£)
Total funds (£)		 Note
Unrestricted
funds(£)
Restricted
funds(£)
Total funds (£)		 Note
Unrestricted
funds(£)
Restricted
funds(£)
Total funds (£)
Other investment
management costs;
Investment management costs 13,645 13,645
-		 -
13,645
Total for 2024
 13,645
Total for 2023

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

69

6. Expenditure on charitable activities

Activity undertaken
directly (£)
Activity
support costs (£)
2024 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2024 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2024 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2024 (£)
Clinoto Journal and other
support costs		 14,003 14,003
574,944		 574,944
588,947
Conference costs 111,050 050
18,376		 376
129,426
ENT UKproduct costs 1,080 1,080
-		 -
1,080
Grants, bursaries and prizes
awarded to individuals		 7,050 7,050
-		 -
7,050
Director of Education costs
~~ee~~		 11,324
~~ee~~		 11,324
-
~~ee~~		 -
11,324
~~ee~~
Subscription to other
relevant bodies		 13,358 13,358
-		 -
13,358
Donations
~~a~~		 95,640 95,640
-		 -
95,640
253,505 505
593,320		 320
846,825
Activity undertaken
directly (£)
Activity
support costs (£)
2023 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2023 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2023 (£)		 Activity undertaken
directly (£)
Activity
support costs (£)
2023 (£)
Clinoto Journal and other
support costs		 14,001 14,001
507,183		 507,183
521,184
Conference costs
a		 597,046 046
200,194		 194
797,240
ENT UKproduct costs
a
~~,~~
~~a~~		 7,613
~~,~~
~~a~~		 7,613
-
~~,~~
~~a~~		 -
7,613
~~,~~
~~a~~
Grants, bursaries and prizes
awarded to individuals
~~a~~		 13,272
~~a~~		 13,272
-
~~a~~		 -
13,272
~~a~~
Director of Education costs 7,595 7,595
-		 -
7,595
Subscription to other
relevant bodies		 13,423 13,423
-		 -
13,423
Donations 45,202 45,202
-		 -
45,202
698,152 152
707,377		 377
1,405,529

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

70

7. Analysis of support costs

Support costs allocated to charitable activities

Governance
Costs(£)
Administration
Costs(£)
Total 2024 (£)
Staff costs
-
410,810
410,810
Travel and meetings expenses
-
20,179
20,179
Website and other computer costs
-
24,250
24,250
Advertisingand marketing
-
13,163
13,163
Rent
-
26,926
26,926
Other office costs
-
22,090
22,090
~~{ff~~
Legal andprofessional fees
-
41,665
41,665
~~a~~
Audit fees
7,000
-
7,000
Accountancyfees
4,000
-
4,000
Depreciation
-
13,428
13,428
Bank and credit charges
-
4,467
4,467
Sundryexpenses
-
5,342
5,342
11,000
582,320
593,320
~~ne Gn~~
~~aeS~~
~~a~~
Governance
costs(£)
Administration
costs(£)
Total 2023 (£)
Staff costs
-
489,639
489,639
Travel and meetings expenses
-
22,798
22,798
~~seen nn~~
Website and other computer costs
-
24,203
24,203
Advertisingand marketing
-
5,665
5,665
Rent
-
29,894
29,894
~~CC~~
Other office costs
-
24,973
24,973
Legal andprofessional fees
-
62,650
62,650
Audit fees
8,491
-
8,491
~~a a~~
~~ee~~
Accountancyfees
4,865
-
4,865
Depreciation
-
12,636
12,636
Bank and credit charges
-
12,443
12,443
Sundryexpenses
-
9,120
9,120
~~a~~
~~ee~~
~~ee~~
13,356
694,021
707,377

8. Net incoming/outgoing resources

Net incoming resources for the year include:

2024(£)
2023(£)		 2024(£)
2023(£)		 2024(£)
2023(£)
Operatingleases - other assets
~~ee~~		 33,420
~~e~~		 420
30,511
~~e~~
Depreciation of fixed assets
~~ee~~		 13,428
~~e~~		 13,428
12,636
~~e~~

BACK TO THE TABLE OF CONTENTS

ENTUK

Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

71

9. Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charitable company during the year.

During the year, 6 Trustees (2023: 4) were reimbursed for reasonable travel and meetings expenses amounting to £2,075 (2023: £3,795).

10. Staff costs

The aggregate payroll costs were as follows:

2024 (£) 2023 (£) STATEMENTS Staff costs during the year were: Wages and salaries 310,708 395,307 AND FINANCIAL ~~———<~~ Social security costs 32,325 29,975 Pension costs 67,777 64,357 410,810 489,639 ~~2~~ The increased staff costs in the prior year is due to the release of prepaid costs relating to the BACO 23 conference that took place in February 2023.

The monthly average number of persons (including senior management team) employed by the charitable company during the year expressed by head count was as follows:

2024(No)
2023(No)		 2024(No)
2023(No)		 2024(No)
2023(No)
Administration 7 7
8

7 (2023 - 8) of the above employees participated in the defined benefit pension scheme. Contributions to the employee pension scheme for the year totalled £67,777 (2023 - £64,357).

The number of employees whose emoluments fell within the following bands was:

2024(No)
2023(No)		 2024(No)
2023(No)		 2024(No)
2023(No)
£70,001 - £80,000 1 1
1

The total employee benefits of the key management personnel of the charitable company were £103,770 (2023 - £97,993).

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

72

11. Intangible fixed assets

Other intangible
Asset(£)
Total (£)		 Other intangible
Asset(£)
Total (£)		 Other intangible
Asset(£)
Total (£)
Cost
~~a~~		 ~~a~~ ~~a~~
Additions
~~a~~		 40,072
~~a~~		 40,072
40,072
~~a~~
At 30 September 2024
~~a~~		 40,072
~~a~~		 072
40,072
~~a~~
Amortisation
At 30 September 2024 - -
-
Net book value
At 30 September 2024 40,072 072
40,072

12. Tangible fixed assets

Computers and office
equipment(£)
Total (£)
~~2~~		 Computers and office
equipment(£)
Total (£)
~~2~~		 Computers and office
equipment(£)
Total (£)
~~2~~
Cost
~~2~~		 ~~2~~ ~~2~~
At 1 October 2023
~~2~~		 205,933
~~2~~		 205,933
205,933
~~2~~
Additions
~~2~~		 14,274
~~2~~		 274
14,274
~~2~~
At 30 September 2024
~~2~~
~~		 ~~
~~		 ~~
Depreciation
~~		 ~~
~~a~~		 ~~
At 1 October 2023
~~a~~		 164,954
~~a~~
~~ee~~		 164,954
164,954
~~a~~
~~ee~~
Charge for theyear
~~a~~		 13,428
~~ee~~
~~a~~		 428
13,428
~~ee~~
~~a~~
At 30 September 2024
~~a~~
~~ee~~		 178,382
~~a~~
~~ee~~		 178,382
178,382
~~a~~
~~ee~~
Net book value
~~ee~~
~~		 ~~
~~		 ~~
At 30 September 2024
~~		 ~~
~~		 ~~
At 30 September 2023
~~		 ~~
~~a~~		 40,979
~~

13. Fixed asset investments

Subsidiary
undertakings (£)
Total (£)		 Subsidiary
undertakings (£)
Total (£)		 Subsidiary
undertakings (£)
Total (£)
Cost
~~a~~		 ~~a~~ ~~a~~
Additions
~~a~~		 1
~~a~~		 1
1
~~a~~
At 30 September 2024 1 1
1
Net book value
At 30 September 2024 1 1
1

Subsidiaries

The financial period end of ENTUK Enterprises Limited is 30 April. The profit for the financial period of ENTUK Enterprises Limited was £Nil (2023 - £Nil) and the aggregate amount of capital and reserves at the end of the period was £Nil (2023 - £Nil).

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

73

ENTUK Enterprises Limited was incorporated on 14 April 2024 with registered company number 15645555.

As the subsidiary is currently immaterial, the charity is not yet required to prepare consolidated financial statements. The subsidiary is disclosed in these accounts at cost.

Details of undertakings

Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~		 Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~		 Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~		 Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~		 Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~		 Undertaking
Country of
incorporation
Holding
Proportion of voting
rights and shares held
Principal
activity
~~a~~
~~eeee~~
~~a~~ ~~a~~ 2024
~~ee~~		 2023
~~ee~~		 ~~ee~~
Subsidiary
undertakings
~~a~~		 ~~a~~ ~~ee~~ ~~ee ~~ ~~ee~~
ENTUK Enterprises
Limited		 England &
Wales		 Ordinary Ordinary
100%		 0% Administration
of the BACO
International
conference
Cost or Valuation
Listed Investments(£)
~~a~~		 Cost or Valuation
Listed Investments(£)
~~a~~
At 1 October 2023
~~a~~		 2,368,086
~~a~~
Revaluation
~~a~~		 272,581
~~a~~
Additions 325,292
Disposals (483,070)
At 30 September 2024 2,482,889
Net book value
At 30 September 2024 2,482,889
At 30 September 2023 2,368,086

At the balance sheet date, the historical cost of the investments was £1,946,785 (2023: £2,104,876).

14. Debtors

2024(£)
2023(£)		 2024(£)
2023(£)		 2024(£)
2023(£)
Trade debtors
~~		 ~~ 39,450
~~
Due fromgroupundertakings
~~		 ~~
~~a~~		 27,832
~~
Intercompanyloans
~~a~~		 55,714
~~a~~		 -
~~a~~
Prepayments 9,939 21,622
Other debtors 1,494 1,193
134,429 69,552

The intercompany loan is an interest-free loan to the subsidiary ENTUK Enterprises Limited. There is no set repayment date, instead being repayable on demand.

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

74

15. Cash and cash equivalents

2024(£)
2023(£)		 2024(£)
2023(£)		 2024(£)
2023(£)
Cash at bank 1,288,646 646
1,087,601

16. Creditors: amounts falling due within one year

2024(£)
2023(£)
Trade creditors
44,257
33,250		 250
Other taxation and social security
12,675
9,552
Other creditors
-
42,468
~~a~~
Pension scheme creditor
6,836
6,973		 6,973
Accruals
102,923
50,842
Deferred income
42,796
38,421
209,487
181,506
~~a~~
~~——————————EE~~
~~a~~
2024(£)
Deferred income at 1 October 2023
38,421
Resources deferred in theperiod
42,796
Amounts released frompreviousperiods
(38,421)
~~a~~
Deferred income at 30 September 2024
42,796
~~a~~
Deferred income relates to delegate and sponsorship income received for future
events.

17. Obligations under leases and hire purchase contracts

Operating lease commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

2024(£)
2023(£)		 2024(£)
2023(£)		 2024(£)
2023(£)
Within oneyear 33,420 420
33,420
Between one and fiveyears 16,710 16,710
50,130
50,130 130
83,550

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

75

18. Pension and other schemes

Defined benefit pension schemes

Superannuation Arrangements of the University of London (SAUL)

The charitable company participates in the Superannuation Arrangements of the University of London (SAUL), which is a centralised defined benefit scheme and is contracted out of the Second State Pension for all eligible employees with the assets held in separate Trustee administered funds.

The charitable company has adopted FRS 102 for accounting pension costs. It is not possible to identify the Charity's share of the underlying assets and liabilities of SAUL. Therefore, contributions are accounted for as if SAUL were a defined contribution scheme and pension costs are based on the amounts actually paid (i.e. cash amounts) in accordance with FRS 102. SAUL is subject to triennial valuations by professionally qualified and independent actuaries.

The last available valuation was carried out as at 31 March 2023 using the projected unit credit method in which the actuarial liability makes allowance for projected earnings.

The main assumptions used to assess the technical provisions were:

As a whole, the market value of the scheme's assets was £3.096 million (31/03/2020: £3.612 million) representing 105% (31/03/2020: 94%) of the liability for benefits after allowing for expected future increases in salaries. The Trustee and the employers agreed to reduce employer contributions to 19% of salaries from 21% as of 1 September 2024. Member contributions will remain unchanged at 6% of salaries.

The total cost relating to defined benefit schemes for the year recognised in profit or loss as an expense was £67,777 (2023 - £64,357).

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

76

19. Funds

Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)		 Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)		 Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)		 Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)		 Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)		 Balance at 1
October 2023
(£)
Incoming
Resources
(£)
Resources
Expended
(£)
Gains, losses
and transfers
(£)
Balance at 30
September
2024(£)
Unrestricted
funds
General fund 2,936,879 2,936,879
737,068		 737,068
(695,307)		 (695,307)
370,479		 370,479
3,349,119
Designated
funds
ENT UK
Foundation		 75,614 75,614
52,450		 52,450
(29,204)		 (29,204)
-		 -
98,860
ST3 Bootcamps
fund		 - -
52,118		 52,118
(12,561)		 (12,561)
-		 -
39,557
BOARS Fund 18,281 18,281
-		 -
(1,500)		 (1,500)
(679)		 (679)
16,102
BSO Fund 33,210 210
8,000		 000
(41,569)		 16,449 449
16,090
Global Health
Committee		 6,099 6,099
-		 -
-		 -
944		 944
7,043
Women in ENT
Surgery		 2,784 2,784
1,665		 1,665
(1,185)		 (1,185)
(1,741)
~~a~~		 (1,741)
1,523
~~a~~
WENTS
mentoring
scheme		 1,547 1,547
-		 -
-		 -
-
~~a~~		 -
1,547
~~a~~
ESC fund - -
-		 -
-		 -
15,471		 471
15,471
ENT UK
drawing
account		 69,123 69,123
54,166		 54,166
-		 -
(92,935)		 (92,935)
30,354
Historyof ENT 1,924 924
-		 -
(42)		 1,068 068
2,950
BACO 54,684 54,684
-		 -
(54,684)		 (54,684)
-		 -
-
Head and Neck
society		 8,284 8,284
-		 -
-		 -
-		 -
8,284
BRS 172,500 172,500
31,500		 31,500
(22,218)		 (22,218)
4,487		 4,487
186,269
SFO 725 725
-		 -
-		 -
-		 -
725
BSFPS 3,058 3,058
2,000		 2,000
(2,200)		 (2,200)
1,623		 1,623
4,481
447,833 833
201,899		 899
(165,163)		 (55,313) 429,256
Total funds 3,384,712 3,384,712
938,967		 938,967
(860,470)		 (860,470)
315,166		 315,166
3,778,375

The specific purposes for which the funds are to be applied are as follows:

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

77

Comparative information in respect of the preceding period is as follows:

Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)		 Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)		 Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)		 Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)		 Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)		 Balance at 1
October
2022(£)
Incoming
resources
(£)
Resources
expended
(£)
Gains, losses
and
transfers(£)
Balance at 30
September
2023(£)
Unrestricted
funds
General fund 2,835,787 2,835,787
1,489,706		 1,489,706
(1,356,441)		 (1,356,441)
(32,173)		 (32,173)
2,936,879
Designated
funds		 ~~ff~~ ~~ff~~
ENT UK
Foundation
~~ee~~		 69,088
~~ee~~		 69,088
56,357
~~ee~~		 56,357
(34,600)
~~ff~~
~~ee~~		 (34,600)
(15,231)
~~ff~~		 (15,231)
75,614
BOARS Fund
~~ee~~		 19,781
~~ee ~~		 781
-
~~ee ~~		 -
-
~~ee~~		 -
(1,500)		 18,281
BSO Fund 30,027 30,027
-		 -
(3,255)		 (3,255)
6,438		 6,438
33,210
Global Health
Committee		 10,547 10,547
3,400		 3,400
(7,974)		 (7,974)
126		 126
6,099
Women in ENT
Surgery		 4,264 4,264
2,250		 2,250
(6,030)		 (6,030)
3,847		 3,847
4,331
ENT UK
drawing
account		 23,740 23,740
-		 -
-		 -
45,383		 45,383
69,123
Historyof ENT
~~po~~		 - -
2,582		 2,582
(658)		 (658)
-		 -
1,924
BACO
~~po~~		 - -
-		 -
-		 -
54,684		 684
54,684
Head and
Neck society
~~po~~
~~ee~~		 -
~~ee~~		 -
-
~~ee~~		 -
-
~~ee~~		 -
8,284		 8,284
8,284
BRS
~~ee~~		 -
~~ee ~~		 -
178,557
~~ee ~~		 557
(8,869)
~~ee~~		 2,812 812
172,500
SFO - -
-		 -
(225)		 (225)
950		 950
725
BSFPS - -
2,000		 000
-		 -
1,058		 058
3,058
157,447 157,447
245,146		 245,146
(61,611)		 (61,611)
106,851		 106,851
447,833
Total funds 2,993,234 234
1,734,852		 852
(1,418,052)		 74,678 678
3,384,712

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

78

20. Analysis of net assets between funds

Unrestricted funds
(£)
Restricted funds (£)
Total funds at 30
September 2023(£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds at 30
September 2023(£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds at 30
September 2023(£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds at 30
September 2023(£)
Tangible fixed
assets		 81,897 81,897
-		 -
81,897
Fixed asset
investments		 2,482,890 2,482,890
-		 -
2,482,890
Current assets 1,423,075 075
-		 -
1,423,075
Current
liabilities		 (209,487) (209,487)
-		 -
(209,487)
Total net assets
 3,778,375 375
-
~~

Prior year:

Unrestricted funds
(£)
Restricted funds (£)
Total funds 2022 (£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds 2022 (£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds 2022 (£)		 Unrestricted funds
(£)
Restricted funds (£)
Total funds 2022 (£)
Tangible fixed
assets		 40,979 40,979
-		 -
40,979
Fixed asset
investments		 2,368,086 2,368,086
-		 -
2,368,086
Current assets 1,170,028 028
-		 -
1,170,028
Current
liabilities
 (181,506)
~~ee~~
~~re~~		 (181,506)
-
~~ee~~
~~re~~
Total net assets
 3,397,587
~~re~~		 587
-
~~re~~

21. Related party transactions

There were no related party transactions in the year.

22. Prior year Statement of Financial Activities

Note
Unrestricted(£)
Restricted(£)
Total 2022(£)		 Note
Unrestricted(£)
Restricted(£)
Total 2022(£)		 Note
Unrestricted(£)
Restricted(£)
Total 2022(£)		 Note
Unrestricted(£)
Restricted(£)
Total 2022(£)		 Note
Unrestricted(£)
Restricted(£)
Total 2022(£)
Income and Endowments from:
~~ee~~		 ~~ee~~ ~~ee~~ ~~ee~~ ~~ee~~
Charitable activities
~~ee~~		 3
~~ee~~
 1,654,392
~~ee~~
~~es~~
Investment income 4
 80,460
~~es~~
Total income 1,734,852 1,734,852
-		 -
1,734,852
Expenditure on:
Raisingfunds 5 12,523 12,523
-		 -
12,523
Charitable activities 6 1,405,529 529
-		 -
1,405,529
Total expenditure
~~a~~		 ~~a~~ 1,418,052
~~a~~		 1,418,052
-
~~a~~		 -
1,418,052
~~a~~
Gains/losses on investment assets
~~a~~
~~a~~		 ~~a~~
~~a~~		 74,678
~~a~~
~~a~~		 678
-
~~a~~
~~a~~		 -
74,678
~~a~~
~~a~~
Net income
~~a~~
~~a~~		 ~~a~~
~~a~~		 391,478
~~a~~
~~a~~		 391,478
-
~~a~~
~~a~~		 -
391,478
~~a~~
~~a~~
Net movement in funds
~~a~~		 ~~a~~
~~		 ~~ 391,478
~~a~~
~~		 ~~
~~oeee~~
Reconciliation of funds ~~ ~~ ~~ ~~
~~oeee~~
Total funds brought forward 2,993,234 234
-		 -
2,993,234
Total funds carried forward 19 3,384,712 3,384,712
-		 -
3,384,712

BACK TO THE TABLE OF CONTENTS

ENTUK

Company registration number: 06452601 Charitable company registration number: 1125524 ANNUAL REPORT 2023 - 2024 || 79

ANNUAL REPORT 2023 - 2024 ||

Principal Office

The Royal College of Surgeons 38-43 Lincoln's Inn Fields, London, WC2A 3PE The charity is incorporated in England and Wales

Company Registration Number

6452601

Charity Registration Number

1125524

VAT No

215668302

Solicitors

SA Law

60 London Road, St Albans, Hertfordshire, AL1 1NG

Bankers

National Westminster Bank Plc

Bloomsbury Parr's, PO Box 158, 214 High Holborn, London, WC1V 7BX

Auditor

Edmund Carr LLP

Chartered Accountants & Statutory Auditor 146 New London Road, Chelmsford, Essex, CM2 0AW

Investment fund managers

Brewin Dolphin Limited

12 Smithfield Street, London, EC1A 9BD

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

80

AAO-HNS
American Academyof Otolaryngology-Head and Neck Surgery
AOMRC
Academyof Medical Royal Colleges
AOT
Association of Otolaryngologists in Training
~~Ot~~
ASGBI
Association of Surgeons of Great Britain and Ireland
ASiT
Association of Surgeons in Training
BACO
British Academic Conference of Otolaryngology
BAETS
British Association of Thyroid and Endocrine Surgeons
BAOMS
British Association or Oral and Maxillofacial Surgeons
BAPO
British Association of Paediatric Otorhinolaryngologists
~~oo~~
~~a~~
BAPRAS
British Association of Plastic Reconstructive and Aesthetic Surgeons
BAPS
British Association of Paediatric Surgeons
BLA
British Laryngological Association
~~EE~~
BOARS
The British Otorhinolaryngologyand Allied Sciences Research Society
~~OO~~
BRS
British Societyof Rhinology
BSACI
British Societyfor Allergyand Clinical Immunology
BSHENT
British Societyfor the Historyof ENT
BSFPS
The British Societyof Facial Plastic Surgery
~~
BSO
The British Societyof Otology
BTA
British Thyroid Association
~~
BVA
British Voice Association
e-lefENT
E-learning platform
~~TO~~
EAFPS
The European Academyof Facial Plastic Surgery
ENT
Common abbreviation for ear, nose and throat
~~EE~~
~~TT~~
ERS
European Rhinological Society
ESPO
The European Societyof Paediatric Otorhinolaryngology
FPS UK
Former name of The British Societyof Facial Plastic Surgery(BSFPS)
FSSA
Federation of Surgical SpecialtyAssociations
GMC
General Medical Council
HNSoc
Head and Neck Society
IOS
Irish Otorhinolaryngology/Head & Neck SurgerySociety
IPC
Independent Practice Committee
MTI
Medical TrainingInitiative
NICE
National Institute for Health and Care Excellence
RCGP
Royal College of General Practitioners
RCN
Royal College of Nursing
~~TT~~
~~COTT~~
RCPSG
Royal College of Physicians and Surgeons of Glasgow
~~EE~~
RCSEd
Royal College of Surgeons of Edinburgh
RCSEng
Royal College of Surgeons of England
RCSI
Royal College of Surgeons of Ireland
RSM
Royal Societyof Medicine
SAC
Special AdvisoryCommittee
SAS
Staff and Associate Specialists (i.e. the ENT Staff and Associate Specialist
Doctors’ Groupof the Education and TrainingCommittee)
SFO UK
Student and Foundation Doctors in Otolaryngology
~~OO~~
~~
TWJ Foundation
Thomas Wickham Jones Foundation
WENTS UK
Women in ENT Surgery
YCOHNS
YoungConsultants in OtolaryngologyHead and Neck Surgery
~~

BACK TO THE TABLE OF CONTENTS

ENTUK Company registration number: 06452601 Charitable company registration number: 1125524

ANNUAL REPORT 2023 - 2024 |

81